Clonidine
Identification
- Summary
Clonidine is an alpha-2 adrenergic agonist used to treat hypertension and severe cancer pain, among other conditions, and to treat withdrawal symptoms from various substances. It is also used to aid in the diagnosis of pheochromocytoma and to prevent migraines.
- Brand Names
- Catapres, Catapres-TTS, Catapres-tts-1, Duraclon, Kapvay, Nexiclon XR
- Generic Name
- Clonidine
- DrugBank Accession Number
- DB00575
- Background
Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.2 This activity is useful for the treatment of hypertension, severe pain, and ADHD.8,9,10,11
Clonidine was granted FDA approval on 3 September 1974.8
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 230.094
Monoisotopic: 229.017352717 - Chemical Formula
- C9H9Cl2N3
- Synonyms
- 2-((2,6-Dichlorophenyl)imino)imidazolidine
- 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
- Chlofazoline
- Clonidin
- Clonidina
- Clonidine
- Clonidinum
- External IDs
- M-5041T
- SKF 34427
- ST 155
- ST 155-BS
Pharmacology
- Indication
Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications.8,9 A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient.10 An extended release tablet of clonidine is indicated for the treatment of ADHD either alone or in combination with other medications.11
Clonidine is also used for the diagnosis of pheochromocytoma,3 treatment of nicotine dependance,4 and opiate withdrawal.5
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Adhd •••••••••••• ••• ••••••••••• •••••••• •••••••• •••••• •••••••• •••••••• ••••••• •••••••• ••••••• Diagnostic agent Growth hormone deficiency ••• ••••• Management of Hot flashes ••• ••••• Management of Hypertension •••••••••••• ••••••• ••••• Symptomatic treatment of Opioid withdrawal ••• ••••• Management of Oppositional defiant disorder ••• ••••• Diagnostic agent Pheochromocytoma ••• ••••• Management of Postherpetic neuralgia ••• ••••• Treatment of Sialorrhea caused by clozapine ••• ••••• Management of Tourette syndrome ••• ••••• Management of Diabetic diarrhea ••• ••••• Symptomatic treatment of Methadone withdrawal ••• ••••• Management of Severe cancer pain •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Clonidine functions through agonism of alpha-2 adrenoceptors which have effects such as lowering blood pressure, sedation, and hyperpolarization of nerves.2 It has a long duration of action as it is given twice daily and the therapeutic window is between 0.1mg and 2.4mg daily.8,9,10,11
- Mechanism of action
Clonidine is primarily an alpha-2 adrenoceptor agonist which causes central hypotensive and anti-arrhythmogenic effects.2 The alpha-2 adrenoceptor is coupled to the G-proteins Go and Gi.2 Gi inhibits adenylyl cyclase and activates opening of a potassium channel that causes hyperpolarization.2 Clonidine binding to the alpha-2 adrenoceptor causes structural changes in the alpha subunit of the G-protein, reducing its affinity for GDP.2 Magnesium catalyzes the replacement of GDP with GTP.2 The alpha subunit dissociates from the other subunits and associates with an effector.2
The stimulation of alpha-2 adrenoceptors in the locus coeruleus may be responsible for the hypnotic effects of clonidine as this region of the brain helps regulate wakefulness.2 Clonidine can also decrease transmission of pain signals at the spine.2 Finally clonidine can affect regulators of blood pressure in the ventromedial and rostral-ventrolateral areas of the medulla.2
Target Actions Organism AAlpha-2B adrenergic receptor agonistHumans AAlpha-2C adrenergic receptor agonistHumans AAlpha-2A adrenergic receptor agonistHumans UAlpha-1A adrenergic receptor agonistHumans UAlpha-1B adrenergic receptor agonistHumans UAlpha-1D adrenergic receptor agonistHumans - Absorption
Clonidine reaches maximum concentration in 60-90 minutes after oral administration.2,6 Race and fasting status do not influence pharmacokinetics of clonidine.8
A 100µg oral clonidine tablet reaches a Cmax of 400.72pg/mL with an AUC of 5606.78h*pg/mL and a bioavailability of 55-87%.6
- Volume of distribution
The volume of distribution of clonidine has been reported as 1.7-2.5L/kg2, 2.9L/kg9, or 2.1±0.4L/kg10 depending on the source.
- Protein binding
Clonidine is 20-40% bound to plasma proteins, especially albumin.2,10
- Metabolism
The metabolism of clonidine is poorly understood.7 The main reaction in clonidine metabolism is the 4-hydroxylation of clonidine by CYP2D6, CYP1A2, CYP3A4, CYP1A1, and CYP3A5.7
Clonidine is <50% metabolized in the liver to inactive metabolites.2,8,9,10,11
Hover over products below to view reaction partners
- Route of elimination
Approximately 50% of a clonidine dose is excreted in the urine as the unchanged drug and 20% is eliminated in the feces.2,8
- Half-life
The elimination half life after epidural administration is 30 minutes but otherwise can range from 6-23h.2
- Clearance
The clearance of clonidine is 1.9-4.3mL/min/kg.2
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Oral LD50 is 126 mg/kg in rats.12 The TDLO is 70µg/kg in children, 126µg/kg in women, and 69µg/kg in men.12
Symptoms of overdose include hypertension followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased reflexes, weakness, irritability, and miosis.8,9,10,11 Severe overdoses can cause reversible cardiac conduction defects or dysrhythmias, apnea, coma, and seizures.8,9,10,11 Induction of vomiting is not recommended due to CNS depression but gastric lavage or activated charcoal may be useful in recent ingestion.8,9,10,11 Dialysis is also unlikely to be beneficial.8,9,10,11 Overdose can be treated with supportive measures such as atropine sulfate for bradycardia, intravenous fluids or vasopressors for hypotension, vasodilators for hypertension, naloxone for respiratory depression, and blood pressure monitoring.8,9,10,11
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of sedation can be increased when Clonidine is combined with 1,2-Benzodiazepine. Abaloparatide The risk or severity of adverse effects can be increased when Clonidine is combined with Abaloparatide. Abametapir The serum concentration of Clonidine can be increased when it is combined with Abametapir. Abatacept The metabolism of Clonidine can be increased when combined with Abatacept. Abiraterone The metabolism of Clonidine can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Clonidine can be decreased when combined with Acalabrutinib. Acebutolol The risk or severity of hypotension can be increased when Clonidine is combined with Acebutolol. Aceclofenac The therapeutic efficacy of Clonidine can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Clonidine can be decreased when used in combination with Acemetacin. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Clonidine. Acetaminophen The metabolism of Clonidine can be increased when combined with Acetaminophen. Acetazolamide The risk or severity of sedation can be increased when Clonidine is combined with Acetazolamide. Acetophenazine The risk or severity of sedation can be increased when Clonidine is combined with Acetophenazine. Acetyldigitoxin Clonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin. Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Clonidine. Aclidinium The risk or severity of Tachycardia can be increased when Clonidine is combined with Aclidinium. Acyclovir The metabolism of Acyclovir can be decreased when combined with Clonidine. Adagrasib The serum concentration of Clonidine can be increased when it is combined with Adagrasib. Adalimumab The metabolism of Clonidine can be increased when combined with Adalimumab. Adenosine The risk or severity of Tachycardia can be increased when Clonidine is combined with Adenosine. Agomelatine The risk or severity of sedation can be increased when Clonidine is combined with Agomelatine. Albendazole The metabolism of Clonidine can be increased when combined with Albendazole. Albuterol Salbutamol may decrease the antihypertensive activities of Clonidine. Alclofenac The therapeutic efficacy of Clonidine can be decreased when used in combination with Alclofenac. Aldesleukin The serum concentration of Clonidine can be increased when it is combined with Aldesleukin. Alfentanil The risk or severity of sedation can be increased when Clonidine is combined with Alfentanil. Alfuzosin Alfuzosin may increase the hypotensive activities of Clonidine. Alimemazine The risk or severity of sedation can be increased when Clonidine is combined with Alimemazine. Aliskiren The risk or severity of hypotension can be increased when Clonidine is combined with Aliskiren. Almotriptan The risk or severity of sedation can be increased when Clonidine is combined with Almotriptan. Alogliptin The metabolism of Clonidine can be decreased when combined with Alogliptin. Alosetron The risk or severity of sedation can be increased when Clonidine is combined with Alosetron. Alpelisib The metabolism of Clonidine can be increased when combined with Alpelisib. Alprazolam The risk or severity of sedation can be increased when Clonidine is combined with Alprazolam. Alverine The risk or severity of sedation can be increased when Clonidine is combined with Alverine. Ambrisentan The risk or severity of hypotension can be increased when Clonidine is combined with Ambrisentan. Amifostine Clonidine may increase the hypotensive activities of Amifostine. Amiloride The risk or severity of adverse effects can be increased when Clonidine is combined with Amiloride. Aminoglutethimide The metabolism of Clonidine can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Clonidine can be decreased when combined with Aminophenazone. Aminophylline The metabolism of Aminophylline can be decreased when combined with Clonidine. Amiodarone Clonidine may increase the atrioventricular blocking (AV block) activities of Amiodarone. Amisulpride The risk or severity of sedation can be increased when Clonidine is combined with Amisulpride. Amitriptyline The risk or severity of sedation can be increased when Clonidine is combined with Amitriptyline. Amitriptylinoxide The risk or severity of sedation can be increased when Clonidine is combined with Amitriptylinoxide. Amlodipine The risk or severity of hypotension can be increased when Clonidine is combined with Amlodipine. Amobarbital The risk or severity of sedation can be increased when Clonidine is combined with Amobarbital. Amoxapine The risk or severity of sedation can be increased when Clonidine is combined with Amoxapine. Amphetamine The metabolism of Clonidine can be decreased when combined with Amphetamine. Amphotericin B The risk or severity of adverse effects can be increased when Clonidine is combined with Amphotericin B. Amprenavir The metabolism of Clonidine can be decreased when combined with Amprenavir. Amyl Nitrite The risk or severity of adverse effects can be increased when Clonidine is combined with Amyl Nitrite. Anagrelide The metabolism of Clonidine can be decreased when combined with Anagrelide. Anakinra The metabolism of Clonidine can be increased when combined with Anakinra. Anileridine The therapeutic efficacy of Anileridine can be increased when used in combination with Clonidine. Anisotropine methylbromide The risk or severity of Tachycardia can be increased when Anisotropine methylbromide is combined with Clonidine. Antipyrine The metabolism of Clonidine can be decreased when combined with Antipyrine. Antrafenine The therapeutic efficacy of Clonidine can be decreased when used in combination with Antrafenine. Apalutamide The serum concentration of Clonidine can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Clonidine can be decreased when combined with Apixaban. Apomorphine The risk or severity of sedation can be increased when Clonidine is combined with Apomorphine. Apremilast The metabolism of Clonidine can be increased when combined with Apremilast. Aprepitant The metabolism of Clonidine can be decreased when combined with Aprepitant. Apronalide The risk or severity of sedation can be increased when Clonidine is combined with Apronalide. Arbutamine Arbutamine may decrease the antihypertensive activities of Clonidine. Arformoterol The metabolism of Clonidine can be decreased when combined with Arformoterol. Aripiprazole The risk or severity of sedation can be increased when Clonidine is combined with Aripiprazole. Aripiprazole lauroxil The risk or severity of sedation can be increased when Clonidine is combined with Aripiprazole lauroxil. Armodafinil The metabolism of Clonidine can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Clonidine is combined with Arsenic trioxide. Artemether The metabolism of Clonidine can be decreased when combined with Artemether. Artenimol The metabolism of Clonidine can be decreased when combined with Artenimol. Articaine The risk or severity of sedation can be increased when Clonidine is combined with Articaine. Asciminib The serum concentration of Clonidine can be increased when it is combined with Asciminib. Asenapine The risk or severity of sedation can be increased when Clonidine is combined with Asenapine. Astemizole The serum concentration of Clonidine can be increased when it is combined with Astemizole. Asunaprevir The metabolism of Clonidine can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Clonidine can be decreased when combined with Atazanavir. Atenolol The risk or severity of hypotension can be increased when Clonidine is combined with Atenolol. Atomoxetine The metabolism of Clonidine can be decreased when combined with Atomoxetine. Atorvastatin The metabolism of Clonidine can be decreased when combined with Atorvastatin. Atracurium The risk or severity of sedation can be increased when Clonidine is combined with Atracurium. Atracurium besylate The risk or severity of sedation can be increased when Clonidine is combined with Atracurium besylate. Atropine Atropine may decrease the antihypertensive activities of Clonidine. Avacopan The serum concentration of Clonidine can be increased when it is combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Clonidine. Axitinib The metabolism of Axitinib can be decreased when combined with Clonidine. Azathioprine The metabolism of Azathioprine can be decreased when combined with Clonidine. Azelastine Clonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Azilsartan medoxomil The risk or severity of hypotension can be increased when Clonidine is combined with Azilsartan medoxomil. Azithromycin The metabolism of Clonidine can be decreased when combined with Azithromycin. Baclofen The risk or severity of sedation can be increased when Clonidine is combined with Baclofen. Balsalazide The therapeutic efficacy of Clonidine can be decreased when used in combination with Balsalazide. Beclomethasone dipropionate The metabolism of Clonidine can be increased when combined with Beclomethasone dipropionate. Belinostat The metabolism of Clonidine can be increased when combined with Belinostat. Belzutifan The serum concentration of Clonidine can be decreased when it is combined with Belzutifan. Benazepril The risk or severity of hypotension can be increased when Clonidine is combined with Benazepril. Bendamustine The metabolism of Bendamustine can be decreased when combined with Clonidine. Bendroflumethiazide The risk or severity of hypotension can be increased when Clonidine is combined with Bendroflumethiazide. Benorilate The therapeutic efficacy of Clonidine can be decreased when used in combination with Benorilate. Benoxaprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Benoxaprofen. Benperidol The risk or severity of sedation can be increased when Clonidine is combined with Benperidol. Benzatropine The metabolism of Clonidine can be decreased when combined with Benzatropine. Benzhydrocodone The risk or severity of hypotension can be increased when Benzhydrocodone is combined with Clonidine. Benzocaine The risk or severity of sedation can be increased when Clonidine is combined with Benzocaine. Benzphetamine The risk or severity of sedation can be increased when Clonidine is combined with Benzphetamine. Benzthiazide The therapeutic efficacy of Clonidine can be increased when used in combination with Benzthiazide. Benzydamine The therapeutic efficacy of Clonidine can be decreased when used in combination with Benzydamine. Benzyl alcohol The risk or severity of sedation can be increased when Clonidine is combined with Benzyl alcohol. Benzylpenicilloyl polylysine Clonidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. Bepridil The risk or severity of hypotension can be increased when Clonidine is combined with Bepridil. Beractant Clonidine may increase the bradycardic activities of Beractant. Berotralstat The serum concentration of Clonidine can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Clonidine can be increased when combined with Betamethasone. Betamethasone phosphate The metabolism of Clonidine can be increased when combined with Betamethasone phosphate. Betaxolol The risk or severity of hypotension can be increased when Clonidine is combined with Betaxolol. Bethanidine The risk or severity of hypotension can be increased when Clonidine is combined with Bethanidine. Bexarotene The metabolism of Clonidine can be increased when combined with Bexarotene. Bicalutamide The metabolism of Clonidine can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Clonidine can be decreased when combined with Bifonazole. Bimatoprost Clonidine may increase the hypotensive activities of Bimatoprost. Bimekizumab The metabolism of Clonidine can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Clonidine. Biperiden The metabolism of Clonidine can be decreased when combined with Biperiden. Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Clonidine. Boceprevir The metabolism of Clonidine can be decreased when combined with Boceprevir. Bortezomib The metabolism of Clonidine can be decreased when combined with Bortezomib. Bosentan The risk or severity of hypotension can be increased when Clonidine is combined with Bosentan. Bosutinib The metabolism of Clonidine can be decreased when combined with Bosutinib. Botulinum toxin type A The risk or severity of sedation can be increased when Clonidine is combined with Botulinum toxin type A. Botulinum toxin type B The risk or severity of sedation can be increased when Clonidine is combined with Botulinum toxin type B. Brentuximab vedotin The serum concentration of Clonidine can be increased when it is combined with Brentuximab vedotin. Bretylium The risk or severity of hypotension can be increased when Clonidine is combined with Bretylium. Brexanolone The risk or severity of sedation can be increased when Clonidine is combined with Brexanolone. Brexpiprazole The risk or severity of sedation can be increased when Clonidine is combined with Brexpiprazole. Brimonidine Brimonidine may increase the antihypertensive activities of Clonidine. Brivaracetam The risk or severity of sedation can be increased when Clonidine is combined with Brivaracetam. Bromazepam The risk or severity of sedation can be increased when Clonidine is combined with Bromazepam. Bromocriptine The risk or severity of sedation can be increased when Clonidine is combined with Bromocriptine. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Clonidine. Bromperidol The risk or severity of sedation can be increased when Clonidine is combined with Bromperidol. Brompheniramine The risk or severity of sedation can be increased when Clonidine is combined with Brompheniramine. Buclizine The risk or severity of Tachycardia can be increased when Buclizine is combined with Clonidine. Budesonide The metabolism of Clonidine can be increased when combined with Budesonide. Bumadizone The therapeutic efficacy of Clonidine can be decreased when used in combination with Bumadizone. Bumetanide The risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide. Bupivacaine The risk or severity of sedation can be increased when Clonidine is combined with Bupivacaine. Buprenorphine The risk or severity of sedation can be increased when Clonidine is combined with Buprenorphine. Bupropion The risk or severity of sedation can be increased when Clonidine is combined with Bupropion. Buspirone The risk or severity of sedation can be increased when Clonidine is combined with Buspirone. Butabarbital The risk or severity of sedation can be increased when Clonidine is combined with Butabarbital. Butalbital The risk or severity of sedation can be increased when Clonidine is combined with Butalbital. Butaperazine The risk or severity of sedation can be increased when Clonidine is combined with Butaperazine. Butobarbital The risk or severity of sedation can be increased when Clonidine is combined with Butobarbital. Butorphanol The risk or severity of sedation can be increased when Clonidine is combined with Butorphanol. Butriptyline The risk or severity of sedation can be increased when Clonidine is combined with Butriptyline. Butylscopolamine The risk or severity of Tachycardia can be increased when Clonidine is combined with Butylscopolamine. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Clonidine. Cabergoline The risk or severity of sedation can be increased when Clonidine is combined with Cabergoline. Caffeine The metabolism of Clonidine can be decreased when combined with Caffeine. Calcitriol The metabolism of Clonidine can be increased when combined with Calcitriol. Calfactant Clonidine may increase the bradycardic activities of Calfactant. Canagliflozin The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin. Canakinumab The metabolism of Clonidine can be increased when combined with Canakinumab. Candesartan cilexetil The risk or severity of hypotension can be increased when Clonidine is combined with Candesartan cilexetil. Candicidin The serum concentration of Clonidine can be increased when it is combined with Candicidin. Cannabidiol The risk or severity of sedation can be increased when Clonidine is combined with Cannabidiol. Capmatinib The serum concentration of Clonidine can be increased when it is combined with Capmatinib. Capsaicin The serum concentration of Clonidine can be increased when it is combined with Capsaicin. Captopril The risk or severity of hypotension can be increased when Clonidine is combined with Captopril. Carbamazepine The risk or severity of sedation can be increased when Clonidine is combined with Carbamazepine. Carbetocin The risk or severity of adverse effects can be increased when Clonidine is combined with Carbetocin. Carbidopa The risk or severity of hypotension can be increased when Carbidopa is combined with Clonidine. Carbinoxamine The risk or severity of sedation can be increased when Clonidine is combined with Carbinoxamine. Cariprazine The risk or severity of sedation can be increased when Clonidine is combined with Cariprazine. Carisoprodol The risk or severity of sedation can be increased when Clonidine is combined with Carisoprodol. Carmustine The metabolism of Clonidine can be decreased when combined with Carmustine. Carprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Carprofen. Carteolol Carteolol may increase the hypotensive activities of Clonidine. Carvedilol The risk or severity of hypotension can be increased when Clonidine is combined with Carvedilol. Cefradine The metabolism of Clonidine can be increased when combined with Cefradine. Celecoxib The metabolism of Clonidine can be decreased when combined with Celecoxib. Celiprolol The risk or severity of hypotension can be increased when Clonidine is combined with Celiprolol. Cenobamate The serum concentration of Clonidine can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Clonidine can be decreased when combined with Cephalexin. Ceritinib Clonidine may increase the bradycardic activities of Ceritinib. Cerivastatin The metabolism of Clonidine can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Clonidine can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of sedation can be increased when Clonidine is combined with Cetirizine. Cevimeline The metabolism of Clonidine can be decreased when combined with Cevimeline. Chloral hydrate The risk or severity of sedation can be increased when Clonidine is combined with Chloral hydrate. Chloramphenicol The serum concentration of Clonidine can be increased when it is combined with Chloramphenicol. Chlordiazepoxide The risk or severity of sedation can be increased when Clonidine is combined with Chlordiazepoxide. Chlormezanone The risk or severity of sedation can be increased when Clonidine is combined with Chlormezanone. Chloroform The therapeutic efficacy of Chloroform can be increased when used in combination with Clonidine. Chloroprocaine The risk or severity of sedation can be increased when Clonidine is combined with Chloroprocaine. Chloroquine The metabolism of Clonidine can be decreased when combined with Chloroquine. Chlorothiazide The risk or severity of hypotension can be increased when Clonidine is combined with Chlorothiazide. Chlorpheniramine The risk or severity of sedation can be increased when Clonidine is combined with Chlorpheniramine. Chlorpromazine The risk or severity of sedation can be increased when Clonidine is combined with Chlorpromazine. Chlorprothixene The risk or severity of sedation can be increased when Clonidine is combined with Chlorprothixene. Chlorzoxazone The risk or severity of sedation can be increased when Clonidine is combined with Chlorzoxazone. Cholecalciferol The metabolism of Clonidine can be decreased when combined with Cholecalciferol. Choline magnesium trisalicylate The therapeutic efficacy of Clonidine can be decreased when used in combination with Choline magnesium trisalicylate. Ciclesonide The metabolism of Clonidine can be decreased when combined with Ciclesonide. Cilazapril The risk or severity of hypotension can be increased when Clonidine is combined with Cilazapril. Cilostazol The metabolism of Clonidine can be decreased when combined with Cilostazol. Cimetidine The metabolism of Clonidine can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Clonidine can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of sedation can be increased when Clonidine is combined with Cinchocaine. Cinnarizine Clonidine may increase the atrioventricular blocking (AV block) activities of Cinnarizine. Cinoxacin The metabolism of Clonidine can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Clonidine can be decreased when combined with Ciprofloxacin. Cisapride The risk or severity of sedation can be increased when Clonidine is combined with Cisapride. Cisatracurium The risk or severity of sedation can be increased when Clonidine is combined with Cisatracurium. Citalopram The risk or severity of sedation can be increased when Clonidine is combined with Citalopram. Clarithromycin The metabolism of Clonidine can be decreased when combined with Clarithromycin. Clemastine The risk or severity of sedation can be increased when Clonidine is combined with Clemastine. Clenbuterol Clenbuterol may decrease the antihypertensive activities of Clonidine. Clevidipine Clonidine may increase the atrioventricular blocking (AV block) activities of Clevidipine. Clidinium The risk or severity of sedation can be increased when Clonidine is combined with Clidinium. Clindamycin The metabolism of Clonidine can be decreased when combined with Clindamycin. Clobazam The risk or severity of sedation can be increased when Clonidine is combined with Clobazam. Clobetasol propionate The metabolism of Clonidine can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clonidine is combined with Clofarabine. Clofazimine The serum concentration of Clonidine can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Clonidine can be increased when combined with Clofibrate. Clomipramine The risk or severity of sedation can be increased when Clonidine is combined with Clomipramine. Clonazepam The risk or severity of sedation can be increased when Clonidine is combined with Clonazepam. Clopidogrel The metabolism of Clonidine can be decreased when combined with Clopidogrel. Clorazepic acid The risk or severity of sedation can be increased when Clonidine is combined with Clorazepic acid. Clothiapine The risk or severity of sedation can be increased when Clonidine is combined with Clothiapine. Clotiazepam The risk or severity of sedation can be increased when Clonidine is combined with Clotiazepam. Clozapine The risk or severity of sedation can be increased when Clonidine is combined with Clozapine. Cobicistat The metabolism of Clonidine can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Clonidine can be decreased when combined with Cobimetinib. Cocaine The metabolism of Clonidine can be decreased when combined with Cocaine. Codeine The risk or severity of sedation can be increased when Clonidine is combined with Codeine. Conivaptan The metabolism of Clonidine can be decreased when combined with Conivaptan. Conjugated estrogens The metabolism of Clonidine can be decreased when combined with Conjugated estrogens. Copanlisib The metabolism of Copanlisib can be decreased when combined with Clonidine. Corticotropin The metabolism of Clonidine can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Clonidine can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Clonidine can be decreased when combined with Crizotinib. Cryptenamine The risk or severity of hypotension can be increased when Clonidine is combined with Cryptenamine. Curcumin The metabolism of Clonidine can be decreased when combined with Curcumin. Cyclandelate Clonidine may increase the atrioventricular blocking (AV block) activities of Cyclandelate. Cyclizine The risk or severity of sedation can be increased when Clonidine is combined with Cyclizine. Cyclobenzaprine The risk or severity of sedation can be increased when Clonidine is combined with Cyclobenzaprine. Cyclopenthiazide The risk or severity of hypotension can be increased when Clonidine is combined with Cyclopenthiazide. Cyclophosphamide The metabolism of Clonidine can be increased when combined with Cyclophosphamide. Cyclosporine The metabolism of Clonidine can be decreased when combined with Cyclosporine. Cyclothiazide The risk or severity of hypotension can be increased when Clonidine is combined with Cyclothiazide. Cycrimine The risk or severity of Tachycardia can be increased when Clonidine is combined with Cycrimine. Cyproheptadine The risk or severity of sedation can be increased when Clonidine is combined with Cyproheptadine. Cyproterone acetate The risk or severity of sedation can be increased when Cyproterone acetate is combined with Clonidine. Dabrafenib The serum concentration of Clonidine can be decreased when it is combined with Dabrafenib. Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Clonidine. Daclatasvir The metabolism of Clonidine can be decreased when combined with Daclatasvir. Dacomitinib The metabolism of Clonidine can be decreased when combined with Dacomitinib. Dalfopristin The metabolism of Clonidine can be decreased when combined with Dalfopristin. Danazol The metabolism of Clonidine can be decreased when combined with Danazol. Dantrolene The risk or severity of sedation can be increased when Clonidine is combined with Dantrolene. Dapagliflozin The risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin. Dapsone The metabolism of Clonidine can be decreased when combined with Dapsone. Daridorexant The risk or severity of sedation can be increased when Clonidine is combined with Daridorexant. Darifenacin The metabolism of Clonidine can be decreased when combined with Darifenacin. Darunavir The serum concentration of Clonidine can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Clonidine can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Clonidine can be decreased when combined with Dasatinib. Dasiglucagon The risk or severity of hypotension can be increased when Clonidine is combined with Dasiglucagon. Daunorubicin The serum concentration of Clonidine can be increased when it is combined with Daunorubicin. Debrisoquine The risk or severity of hypotension can be increased when Clonidine is combined with Debrisoquine. Decamethonium The risk or severity of sedation can be increased when Clonidine is combined with Decamethonium. Deferasirox The serum concentration of Clonidine can be increased when it is combined with Deferasirox. Deflazacort The metabolism of Clonidine can be increased when combined with Deflazacort. Delavirdine The metabolism of Clonidine can be decreased when combined with Delavirdine. Deserpidine The risk or severity of hypotension can be increased when Clonidine is combined with Deserpidine. Desflurane The risk or severity of sedation can be increased when Clonidine is combined with Desflurane. Desipramine The risk or severity of sedation can be increased when Clonidine is combined with Desipramine. Deslanoside Clonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside. Desloratadine The risk or severity of sedation can be increased when Clonidine is combined with Desloratadine. Desmopressin Desmopressin may decrease the antihypertensive activities of Clonidine. Desogestrel The risk or severity of sedation can be increased when Desogestrel is combined with Clonidine. Desvenlafaxine The risk or severity of sedation can be increased when Clonidine is combined with Desvenlafaxine. Deutetrabenazine The metabolism of Clonidine can be decreased when combined with Deutetrabenazine. Dexamethasone The metabolism of Clonidine can be increased when combined with Dexamethasone. Dexamethasone acetate The metabolism of Clonidine can be increased when combined with Dexamethasone acetate. Dexbrompheniramine The risk or severity of sedation can be increased when Clonidine is combined with Dexbrompheniramine. Dexchlorpheniramine maleate The metabolism of Clonidine can be decreased when combined with Dexchlorpheniramine maleate. Dexfenfluramine The metabolism of Clonidine can be decreased when combined with Dexfenfluramine. Dexibuprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Dexibuprofen. Dexketoprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Dexketoprofen. Dexmedetomidine The risk or severity of sedation can be increased when Clonidine is combined with Dexmedetomidine. Dexmethylphenidate The risk or severity of sedation can be increased when Clonidine is combined with Dexmethylphenidate. Dextroamphetamine The metabolism of Clonidine can be decreased when combined with Dextroamphetamine. Dextromethorphan The risk or severity of sedation can be increased when Clonidine is combined with Dextromethorphan. Dextropropoxyphene The risk or severity of sedation can be increased when Clonidine is combined with Dextropropoxyphene. Dezocine The risk or severity of sedation can be increased when Clonidine is combined with Dezocine. Diacerein The metabolism of Clonidine can be decreased when combined with Diacerein. Diamorphine The risk or severity of sedation can be increased when Clonidine is combined with Diamorphine. Diazepam The risk or severity of sedation can be increased when Clonidine is combined with Diazepam. Diazoxide Diazoxide may increase the hypotensive activities of Clonidine. Dibenzepin The risk or severity of sedation can be increased when Clonidine is combined with Dibenzepin. Dichloralphenazone The risk or severity of sedation can be increased when Clonidine is combined with Dichloralphenazone. Diclofenac The therapeutic efficacy of Clonidine can be decreased when used in combination with Diclofenac. Diclofenamide The risk or severity of adverse effects can be increased when Clonidine is combined with Diclofenamide. Dicloxacillin The metabolism of Clonidine can be increased when combined with Dicloxacillin. Dicyclomine The risk or severity of Tachycardia can be increased when Clonidine is combined with Dicyclomine. Dienogest The risk or severity of sedation can be increased when Dienogest is combined with Clonidine. Diethylpropion The risk or severity of sedation can be increased when Clonidine is combined with Diethylpropion. Diethylstilbestrol The serum concentration of Clonidine can be increased when it is combined with Diethylstilbestrol. Difenoxin The risk or severity of sedation can be increased when Clonidine is combined with Difenoxin. Diflunisal The therapeutic efficacy of Clonidine can be decreased when used in combination with Diflunisal. Difluocortolone The metabolism of Clonidine can be increased when combined with Difluocortolone. Digitoxin Clonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin. Digoxin Clonidine may increase the atrioventricular blocking (AV block) activities of Digoxin. Dihydralazine The risk or severity of hypotension can be increased when Clonidine is combined with Dihydralazine. Dihydrocodeine The risk or severity of sedation can be increased when Clonidine is combined with Dihydrocodeine. Dihydroergocornine Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Clonidine. Dihydroergocristine Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Clonidine. Dihydroergotamine The risk or severity of sedation can be increased when Clonidine is combined with Dihydroergotamine. Diltiazem Diltiazem may increase the atrioventricular blocking (AV block) activities of Clonidine. Dimenhydrinate The risk or severity of sedation can be increased when Clonidine is combined with Dimenhydrinate. Dimethyl sulfoxide The serum concentration of Clonidine can be increased when it is combined with Dimethyl sulfoxide. Dimetindene The risk or severity of Tachycardia can be increased when Clonidine is combined with Dimetindene. Dinutuximab The risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab. Diosmin The serum concentration of Clonidine can be increased when it is combined with Diosmin. Diphemanil The risk or severity of Tachycardia can be increased when Clonidine is combined with Diphemanil. Diphenhydramine The risk or severity of sedation can be increased when Clonidine is combined with Diphenhydramine. Diphenidol The risk or severity of Tachycardia can be increased when Clonidine is combined with Diphenidol. Diphenoxylate The risk or severity of sedation can be increased when Clonidine is combined with Diphenoxylate. Dipyridamole Dipyridamole may increase the antihypertensive activities of Clonidine. Disopyramide The metabolism of Clonidine can be decreased when combined with Disopyramide. Disulfiram The metabolism of Clonidine can be decreased when combined with Disulfiram. DL-Methylephedrine DL-Methylephedrine may decrease the antihypertensive activities of Clonidine. Dobutamine Dobutamine may decrease the antihypertensive activities of Clonidine. Docetaxel The serum concentration of Clonidine can be increased when it is combined with Docetaxel. Dolasetron The risk or severity of sedation can be increased when Clonidine is combined with Dolasetron. Domperidone The metabolism of Clonidine can be decreased when combined with Domperidone. Donepezil The risk or severity of sedation can be increased when Clonidine is combined with Donepezil. Dopamine Dopamine may decrease the antihypertensive activities of Clonidine. Dopexamine Dopexamine may decrease the antihypertensive activities of Clonidine. Doravirine The metabolism of Clonidine can be decreased when combined with Doravirine. Dorzolamide Clonidine may increase the hypotensive activities of Dorzolamide. Dosulepin The risk or severity of sedation can be increased when Clonidine is combined with Dosulepin. Doxacurium The risk or severity of sedation can be increased when Clonidine is combined with Doxacurium. Doxapram Doxapram may decrease the antihypertensive activities of Clonidine. Doxazosin The risk or severity of hypotension can be increased when Clonidine is combined with Doxazosin. Doxepin The risk or severity of sedation can be increased when Clonidine is combined with Doxepin. Doxorubicin The serum concentration of Clonidine can be increased when it is combined with Doxorubicin. Doxylamine The risk or severity of sedation can be increased when Clonidine is combined with Doxylamine. Dronabinol The risk or severity of sedation can be increased when Clonidine is combined with Dronabinol. Dronedarone The serum concentration of Clonidine can be increased when it is combined with Dronedarone. Droperidol The risk or severity of sedation can be increased when Clonidine is combined with Droperidol. Drospirenone The risk or severity of sedation can be increased when Drospirenone is combined with Clonidine. Droxidopa Droxidopa may decrease the antihypertensive activities of Clonidine. Duloxetine The risk or severity of sedation can be increased when Clonidine is combined with Duloxetine. Dutasteride The metabolism of Clonidine can be decreased when combined with Dutasteride. Duvelisib The metabolism of Clonidine can be decreased when combined with Duvelisib. Dyclonine The risk or severity of sedation can be increased when Clonidine is combined with Dyclonine. Ebastine The metabolism of Clonidine can be decreased when combined with Ebastine. Echinacea The metabolism of Clonidine can be increased when combined with Echinacea. Efavirenz The risk or severity of sedation can be increased when Clonidine is combined with Efavirenz. Elagolix The metabolism of Clonidine can be decreased when combined with Elagolix. Elbasvir The metabolism of Clonidine can be decreased when combined with Elbasvir. Eletriptan The risk or severity of sedation can be increased when Clonidine is combined with Eletriptan. Elexacaftor The metabolism of Clonidine can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Clonidine can be decreased when combined with Eliglustat. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Clonidine. Eluxadoline The risk or severity of hypotension can be increased when Eluxadoline is combined with Clonidine. Elvitegravir The metabolism of Clonidine can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Clonidine can be increased when combined with Emapalumab. Empagliflozin The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin. Enalapril The risk or severity of hypotension can be increased when Clonidine is combined with Enalapril. Enalaprilat The risk or severity of hypotension can be increased when Clonidine is combined with Enalaprilat. Enasidenib The metabolism of Clonidine can be increased when combined with Enasidenib. Encainide The metabolism of Clonidine can be decreased when combined with Encainide. Encorafenib The metabolism of Clonidine can be increased when combined with Encorafenib. Enflurane The risk or severity of sedation can be increased when Clonidine is combined with Enflurane. Enoxacin The metabolism of Clonidine can be decreased when combined with Enoxacin. Entacapone The risk or severity of sedation can be increased when Clonidine is combined with Entacapone. Entecavir The metabolism of Clonidine can be decreased when combined with Entecavir. Enzalutamide The serum concentration of Clonidine can be decreased when it is combined with Enzalutamide. Epcoritamab The serum concentration of Clonidine can be increased when it is combined with Epcoritamab. Ephedrine Ephedrine may decrease the antihypertensive activities of Clonidine. Epinastine The risk or severity of sedation can be increased when Clonidine is combined with Epinastine. Epinephrine The serum concentration of Clonidine can be increased when it is combined with Epinephrine. Eplerenone The risk or severity of hypotension can be increased when Clonidine is combined with Eplerenone. Epoprostenol The risk or severity of hypotension can be increased when Clonidine is combined with Epoprostenol. Eprosartan The risk or severity of hypotension can be increased when Clonidine is combined with Eprosartan. Erdafitinib The serum concentration of Clonidine can be increased when it is combined with Erdafitinib. Ergoloid mesylate The risk or severity of sedation can be increased when Clonidine is combined with Ergoloid mesylate. Ergometrine The risk or severity of sedation can be increased when Clonidine is combined with Ergometrine. Ergotamine The risk or severity of sedation can be increased when Clonidine is combined with Ergotamine. Erlotinib The serum concentration of Clonidine can be increased when it is combined with Erlotinib. Erythromycin The serum concentration of Clonidine can be increased when it is combined with Erythromycin. Escitalopram The risk or severity of sedation can be increased when Clonidine is combined with Escitalopram. Esketamine The risk or severity of sedation can be increased when Clonidine is combined with Esketamine. Eslicarbazepine The risk or severity of sedation can be increased when Clonidine is combined with Eslicarbazepine. Eslicarbazepine acetate The risk or severity of sedation can be increased when Clonidine is combined with Eslicarbazepine acetate. Esmolol The risk or severity of hypotension can be increased when Clonidine is combined with Esmolol. Estazolam The risk or severity of sedation can be increased when Clonidine is combined with Estazolam. Estetrol The risk or severity of sedation can be increased when Estetrol is combined with Clonidine. Estradiol The risk or severity of sedation can be increased when Estradiol is combined with Clonidine. Estradiol acetate The metabolism of Clonidine can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Clonidine can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Clonidine can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Clonidine can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Clonidine can be increased when combined with Estradiol valerate. Estrone sulfate The metabolism of Clonidine can be decreased when combined with Estrone sulfate. Eszopiclone The risk or severity of sedation can be increased when Clonidine is combined with Eszopiclone. Etacrynic acid The risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid. Etafedrine Etafedrine may decrease the antihypertensive activities of Clonidine. Etanercept The metabolism of Clonidine can be increased when combined with Etanercept. Ethambutol The metabolism of Clonidine can be decreased when combined with Ethambutol. Ethanol Ethanol may increase the central nervous system depressant (CNS depressant) activities of Clonidine. Ethchlorvynol The risk or severity of sedation can be increased when Clonidine is combined with Ethchlorvynol. Ethinylestradiol The risk or severity of sedation can be increased when Ethinylestradiol is combined with Clonidine. Ethosuximide The risk or severity of sedation can be increased when Clonidine is combined with Ethosuximide. Ethotoin The risk or severity of sedation can be increased when Clonidine is combined with Ethotoin. Ethynodiol diacetate The risk or severity of sedation can be increased when Ethynodiol diacetate is combined with Clonidine. Etilefrine Etilefrine may decrease the antihypertensive activities of Clonidine. Etodolac The therapeutic efficacy of Clonidine can be decreased when used in combination with Etodolac. Etomidate The risk or severity of sedation can be increased when Clonidine is combined with Etomidate. Etoposide The metabolism of Etoposide can be decreased when combined with Clonidine. Etoricoxib The serum concentration of Clonidine can be increased when it is combined with Etoricoxib. Etravirine The metabolism of Clonidine can be increased when combined with Etravirine. Everolimus The metabolism of Clonidine can be decreased when combined with Everolimus. Ezogabine The risk or severity of sedation can be increased when Clonidine is combined with Ezogabine. Famotidine The metabolism of Clonidine can be decreased when combined with Famotidine. Fedratinib The serum concentration of Clonidine can be increased when it is combined with Fedratinib. Felbamate The risk or severity of sedation can be increased when Clonidine is combined with Felbamate. Felodipine The risk or severity of hypotension can be increased when Clonidine is combined with Felodipine. Fenbufen The therapeutic efficacy of Clonidine can be decreased when used in combination with Fenbufen. Fenfluramine The risk or severity of sedation can be increased when Clonidine is combined with Fenfluramine. Fenofibrate The metabolism of Clonidine can be decreased when combined with Fenofibrate. Fenoldopam The risk or severity of hypotension can be increased when Clonidine is combined with Fenoldopam. Fenoprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Fenoprofen. Fenoterol Fenoterol may decrease the antihypertensive activities of Clonidine. Fentanyl The risk or severity of sedation can be increased when Clonidine is combined with Fentanyl. Fesoterodine The metabolism of Clonidine can be decreased when combined with Fesoterodine. Fexinidazole The risk or severity of adverse effects can be increased when Clonidine is combined with Fexinidazole. Fezolinetant The metabolism of Fezolinetant can be decreased when combined with Clonidine. Filgotinib The serum concentration of Clonidine can be increased when it is combined with Filgotinib. Finasteride The metabolism of Clonidine can be decreased when combined with Finasteride. Fingolimod Clonidine may increase the bradycardic activities of Fingolimod. Flavoxate The risk or severity of Tachycardia can be increased when Clonidine is combined with Flavoxate. Flecainide The metabolism of Clonidine can be decreased when combined with Flecainide. Flibanserin The risk or severity of sedation can be increased when Clonidine is combined with Flibanserin. Floctafenine The therapeutic efficacy of Clonidine can be decreased when used in combination with Floctafenine. Flucloxacillin The metabolism of Clonidine can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Clonidine can be decreased when combined with Fluconazole. Flunarizine The risk or severity of sedation can be increased when Clonidine is combined with Flunarizine. Flunisolide The metabolism of Clonidine can be increased when combined with Flunisolide. Flunitrazepam The risk or severity of sedation can be increased when Clonidine is combined with Flunitrazepam. Fluocinolone acetonide The metabolism of Clonidine can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Clonidine can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Clonidine can be increased when combined with Fluocortolone. Fluorouracil The metabolism of Clonidine can be decreased when combined with Fluorouracil. Fluoxetine The risk or severity of sedation can be increased when Clonidine is combined with Fluoxetine. Flupentixol The risk or severity of sedation can be increased when Clonidine is combined with Flupentixol. Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Clonidine. Flurazepam The risk or severity of sedation can be increased when Clonidine is combined with Flurazepam. Flurbiprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Flurbiprofen. Fluspirilene The risk or severity of sedation can be increased when Clonidine is combined with Fluspirilene. Flutamide The metabolism of Clonidine can be decreased when combined with Flutamide. Fluticasone The metabolism of Clonidine can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Clonidine can be decreased when combined with Fluticasone furoate. Fluticasone propionate The risk or severity of sedation can be increased when Clonidine is combined with Fluticasone propionate. Fluvastatin The metabolism of Clonidine can be decreased when combined with Fluvastatin. Fluvoxamine The risk or severity of sedation can be increased when Clonidine is combined with Fluvoxamine. Formestane The metabolism of Clonidine can be increased when combined with Formestane. Formoterol Clonidine may increase the sympathomimetic activities of Formoterol. Fosamprenavir The serum concentration of Clonidine can be increased when it is combined with Fosamprenavir. Fosaprepitant The metabolism of Clonidine can be increased when combined with Fosaprepitant. Fosinopril The risk or severity of hypotension can be increased when Clonidine is combined with Fosinopril. Fosnetupitant The metabolism of Clonidine can be decreased when combined with Fosnetupitant. Fosphenytoin The risk or severity of sedation can be increased when Clonidine is combined with Fosphenytoin. Fospropofol The risk or severity of sedation can be increased when Clonidine is combined with Fospropofol. Fostamatinib The serum concentration of Clonidine can be increased when it is combined with Fostamatinib. Frovatriptan The risk or severity of sedation can be increased when Clonidine is combined with Frovatriptan. Fruquintinib The metabolism of Clonidine can be decreased when combined with Fruquintinib. Furosemide The risk or severity of hypotension can be increased when Clonidine is combined with Furosemide. Fusidic acid The metabolism of Clonidine can be decreased when combined with Fusidic acid. Gabapentin The risk or severity of sedation can be increased when Clonidine is combined with Gabapentin. Gabapentin enacarbil The risk or severity of sedation can be increased when Clonidine is combined with Gabapentin enacarbil. Galantamine The metabolism of Clonidine can be decreased when combined with Galantamine. Gallamine triethiodide The risk or severity of sedation can be increased when Clonidine is combined with Gallamine triethiodide. gamma-Hydroxybutyric acid The risk or severity of sedation can be increased when Clonidine is combined with gamma-Hydroxybutyric acid. Ganaxolone The risk or severity of sedation can be increased when Clonidine is combined with Ganaxolone. Gatifloxacin The metabolism of Clonidine can be decreased when combined with Gatifloxacin. Gefitinib The metabolism of Clonidine can be decreased when combined with Gefitinib. Gemfibrozil The metabolism of Clonidine can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Clonidine can be decreased when combined with Gemifloxacin. Gepirone The risk or severity of sedation can be increased when Clonidine is combined with Gepirone. Gestrinone The risk or severity of sedation can be increased when Gestrinone is combined with Clonidine. Gilteritinib The metabolism of Clonidine can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Clonidine can be decreased when combined with Ginkgo biloba. Givinostat The serum concentration of Clonidine can be increased when it is combined with Givinostat. Givosiran The serum concentration of Clonidine can be increased when it is combined with Givosiran. Glecaprevir The metabolism of Clonidine can be decreased when combined with Glecaprevir. Glofitamab The serum concentration of Clonidine can be increased when it is combined with Glofitamab. Glutethimide The risk or severity of sedation can be increased when Clonidine is combined with Glutethimide. Glyburide The metabolism of Clonidine can be decreased when combined with Glyburide. Glycerol phenylbutyrate The metabolism of Clonidine can be increased when combined with Glycerol phenylbutyrate. Glycol salicylate The therapeutic efficacy of Clonidine can be decreased when used in combination with Glycol salicylate. Glycopyrronium The risk or severity of Tachycardia can be increased when Clonidine is combined with Glycopyrronium. Golimumab The metabolism of Clonidine can be increased when combined with Golimumab. Granisetron The risk or severity of sedation can be increased when Clonidine is combined with Granisetron. Grapefruit The serum concentration of Clonidine can be increased when it is combined with Grapefruit. Grepafloxacin The metabolism of Clonidine can be decreased when combined with Grepafloxacin. Griseofulvin The metabolism of Clonidine can be increased when combined with Griseofulvin. Guanabenz The risk or severity of hypotension can be increased when Clonidine is combined with Guanabenz. Guanadrel The risk or severity of hypotension can be increased when Clonidine is combined with Guanadrel. Guanethidine The risk or severity of hypotension can be increased when Clonidine is combined with Guanethidine. Guanfacine The risk or severity of sedation can be increased when Clonidine is combined with Guanfacine. Guanoxan The risk or severity of hypotension can be increased when Clonidine is combined with Guanoxan. Halazepam The risk or severity of sedation can be increased when Clonidine is combined with Halazepam. Halofantrine The metabolism of Clonidine can be decreased when combined with Halofantrine. Haloperidol The risk or severity of sedation can be increased when Clonidine is combined with Haloperidol. Halothane The risk or severity of sedation can be increased when Clonidine is combined with Halothane. Hexafluronium The risk or severity of sedation can be increased when Clonidine is combined with Hexafluronium. Hexocyclium The risk or severity of Tachycardia can be increased when Clonidine is combined with Hexocyclium. Homatropine methylbromide The risk or severity of Tachycardia can be increased when Clonidine is combined with Homatropine methylbromide. Hyaluronidase The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Clonidine. Hyaluronidase (human recombinant) The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Clonidine. Hyaluronidase (ovine) The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Clonidine. Hydralazine The risk or severity of hypotension can be increased when Clonidine is combined with Hydralazine. Hydrochlorothiazide The risk or severity of hypotension can be increased when Clonidine is combined with Hydrochlorothiazide. Hydrocodone The risk or severity of sedation can be increased when Clonidine is combined with Hydrocodone. Hydrocortamate The metabolism of Clonidine can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Clonidine can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Clonidine can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Clonidine can be increased when combined with Hydrocortisone butyrate. Hydrocortisone cypionate The metabolism of Clonidine can be decreased when combined with Hydrocortisone cypionate. Hydrocortisone phosphate The metabolism of Clonidine can be decreased when combined with Hydrocortisone phosphate. Hydrocortisone succinate The metabolism of Clonidine can be increased when combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of hypotension can be increased when Clonidine is combined with Hydroflumethiazide. Hydromorphone The risk or severity of sedation can be increased when Clonidine is combined with Hydromorphone. Hydroxychloroquine The metabolism of Clonidine can be decreased when combined with Hydroxychloroquine. Hydroxyprogesterone caproate The metabolism of Clonidine can be decreased when combined with Hydroxyprogesterone caproate. Hydroxyzine The risk or severity of sedation can be increased when Clonidine is combined with Hydroxyzine. Hyoscyamine The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Clonidine. Ibrutinib The metabolism of Clonidine can be decreased when combined with Ibrutinib. Ibuprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Ibuprofen. Icosapent The therapeutic efficacy of Clonidine can be decreased when used in combination with Icosapent. Idarubicin The metabolism of Clonidine can be decreased when combined with Idarubicin. Idelalisib The metabolism of Clonidine can be decreased when combined with Idelalisib. Ifosfamide The metabolism of Clonidine can be increased when combined with Ifosfamide. Iloperidone The risk or severity of sedation can be increased when Clonidine is combined with Iloperidone. Iloprost Iloprost may increase the hypotensive activities of Clonidine. Imatinib The serum concentration of Clonidine can be increased when it is combined with Imatinib. Imipramine The risk or severity of sedation can be increased when Clonidine is combined with Imipramine. Indacaterol Indacaterol may decrease the antihypertensive activities of Clonidine. Indapamide The risk or severity of hypotension can be increased when Clonidine is combined with Indapamide. Indinavir The metabolism of Clonidine can be decreased when combined with Indinavir. Indomethacin The therapeutic efficacy of Clonidine can be decreased when used in combination with Indomethacin. Indoramin The risk or severity of hypotension can be increased when Clonidine is combined with Indoramin. Infigratinib The metabolism of Clonidine can be decreased when combined with Infigratinib. Infliximab The metabolism of Clonidine can be increased when combined with Infliximab. Insulin aspart The therapeutic efficacy of Insulin aspart can be increased when used in combination with Clonidine. Insulin beef The therapeutic efficacy of Insulin beef can be increased when used in combination with Clonidine. Insulin degludec The therapeutic efficacy of Insulin degludec can be increased when used in combination with Clonidine. Insulin detemir The therapeutic efficacy of Insulin detemir can be increased when used in combination with Clonidine. Insulin glargine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Clonidine. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Clonidine. Insulin human The therapeutic efficacy of Insulin human can be increased when used in combination with Clonidine. Insulin lispro The therapeutic efficacy of Insulin lispro can be increased when used in combination with Clonidine. Insulin pork The therapeutic efficacy of Insulin pork can be increased when used in combination with Clonidine. Interferon alfa-2a The metabolism of Clonidine can be decreased when combined with Interferon alfa-2a. Interferon alfa-2b The metabolism of Clonidine can be decreased when combined with Interferon alfa-2b. Interferon alfa-n1 The metabolism of Clonidine can be decreased when combined with Interferon alfa-n1. Interferon alfa-n3 The metabolism of Clonidine can be decreased when combined with Interferon alfa-n3. Interferon alfacon-1 The metabolism of Clonidine can be decreased when combined with Interferon alfacon-1. Interferon beta-1a The metabolism of Clonidine can be decreased when combined with Interferon beta-1a. Interferon beta-1b The metabolism of Clonidine can be decreased when combined with Interferon beta-1b. Interferon gamma-1b The metabolism of Clonidine can be decreased when combined with Interferon gamma-1b. Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Clonidine. Iofetamine I-123 Iofetamine I-123 may decrease the antihypertensive activities of Clonidine. Ipecac The metabolism of Clonidine can be decreased when combined with Ipecac. Ipratropium The risk or severity of Tachycardia can be increased when Ipratropium is combined with Clonidine. Iptacopan The metabolism of Clonidine can be decreased when combined with Iptacopan. Irbesartan The risk or severity of hypotension can be increased when Clonidine is combined with Irbesartan. Irinotecan The metabolism of Clonidine can be decreased when combined with Irinotecan. Isavuconazole The metabolism of Clonidine can be increased when combined with Isavuconazole. Isavuconazonium The metabolism of Clonidine can be increased when combined with Isavuconazonium. Isocarboxazid The risk or severity of sedation can be increased when Clonidine is combined with Isocarboxazid. Isoetharine Isoetharine may decrease the antihypertensive activities of Clonidine. Isoflurane The risk or severity of sedation can be increased when Clonidine is combined with Isoflurane. Isometheptene Isometheptene may decrease the antihypertensive activities of Clonidine. Isoniazid The metabolism of Clonidine can be decreased when combined with Isoniazid. Isoprenaline Isoprenaline may decrease the antihypertensive activities of Clonidine. Isopropamide The risk or severity of Tachycardia can be increased when Clonidine is combined with Isopropamide. Isosorbide dinitrate The risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide dinitrate. Isosorbide mononitrate The risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide mononitrate. Isoxicam The therapeutic efficacy of Clonidine can be decreased when used in combination with Isoxicam. Isoxsuprine Isoxsuprine may decrease the antihypertensive activities of Clonidine. Isradipine The risk or severity of hypotension can be increased when Clonidine is combined with Isradipine. Istradefylline The metabolism of Clonidine can be decreased when combined with Istradefylline. Itraconazole The metabolism of Clonidine can be decreased when combined with Itraconazole. Ivabradine Clonidine may increase the bradycardic activities of Ivabradine. Ivacaftor The serum concentration of Clonidine can be increased when it is combined with Ivacaftor. Ivosidenib The metabolism of Clonidine can be increased when combined with Ivosidenib. Ketamine The risk or severity of sedation can be increased when Clonidine is combined with Ketamine. Ketazolam The risk or severity of sedation can be increased when Clonidine is combined with Ketazolam. Ketoconazole The metabolism of Clonidine can be decreased when combined with Ketoconazole. Ketoprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Ketoprofen. Ketorolac The therapeutic efficacy of Clonidine can be decreased when used in combination with Ketorolac. Labetalol The risk or severity of hypotension can be increased when Clonidine is combined with Labetalol. Lacidipine Clonidine may increase the hypotensive activities of Lacidipine. Lacosamide The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Clonidine is combined with Lacosamide. Lamotrigine The risk or severity of sedation can be increased when Clonidine is combined with Lamotrigine. Lanreotide The metabolism of Clonidine can be decreased when combined with Lanreotide. Lansoprazole The metabolism of Clonidine can be decreased when combined with Lansoprazole. Lapatinib The metabolism of Clonidine can be decreased when combined with Lapatinib. Lasmiditan The risk or severity of sedation can be increased when Clonidine is combined with Lasmiditan. Lefamulin The serum concentration of Clonidine can be increased when it is combined with Lefamulin. Leflunomide The serum concentration of Clonidine can be decreased when it is combined with Leflunomide. Lemborexant The risk or severity of sedation can be increased when Clonidine is combined with Lemborexant. Lenacapavir The metabolism of Clonidine can be decreased when combined with Lenacapavir. Leniolisib The metabolism of Clonidine can be decreased when combined with Leniolisib. Lercanidipine The risk or severity of hypotension can be increased when Clonidine is combined with Lercanidipine. Lesinurad The metabolism of Clonidine can be increased when combined with Lesinurad. Letermovir The serum concentration of Clonidine can be increased when it is combined with Letermovir. Levacetylmethadol The risk or severity of sedation can be increased when Clonidine is combined with Levacetylmethadol. Levamlodipine The risk or severity of hypotension can be increased when Clonidine is combined with Levamlodipine. Levetiracetam The risk or severity of sedation can be increased when Clonidine is combined with Levetiracetam. Levobetaxolol The metabolism of Clonidine can be decreased when combined with Levobetaxolol. Levobupivacaine The risk or severity of sedation can be increased when Clonidine is combined with Levobupivacaine. Levocabastine The risk or severity of sedation can be increased when Clonidine is combined with Levocabastine. Levocetirizine The risk or severity of sedation can be increased when Clonidine is combined with Levocetirizine. Levodopa The risk or severity of sedation can be increased when Clonidine is combined with Levodopa. Levoketoconazole The metabolism of Clonidine can be decreased when combined with Levoketoconazole. Levomenthol Clonidine may increase the bradycardic activities of Levomenthol. Levomilnacipran Levomilnacipran may increase the tachycardic activities of Clonidine. Levonordefrin Levonordefrin may decrease the antihypertensive activities of Clonidine. Levonorgestrel The risk or severity of sedation can be increased when Levonorgestrel is combined with Clonidine. Levorphanol The risk or severity of sedation can be increased when Clonidine is combined with Levorphanol. Levosalbutamol Levosalbutamol may decrease the antihypertensive activities of Clonidine. Levosimendan The risk or severity of adverse effects can be increased when Clonidine is combined with Levosimendan. Lidocaine The risk or severity of sedation can be increased when Clonidine is combined with Lidocaine. Lidoflazine Clonidine may increase the atrioventricular blocking (AV block) activities of Lidoflazine. Linagliptin The metabolism of Clonidine can be decreased when combined with Linagliptin. Linezolid Linezolid may increase the hypertensive activities of Clonidine. Lisdexamfetamine Lisdexamfetamine may decrease the antihypertensive activities of Clonidine. Lisinopril The risk or severity of hypotension can be increased when Clonidine is combined with Lisinopril. Lisuride The risk or severity of sedation can be increased when Clonidine is combined with Lisuride. Lithium carbonate The risk or severity of sedation can be increased when Clonidine is combined with Lithium carbonate. Lofexidine The risk or severity of sedation can be increased when Clonidine is combined with Lofexidine. Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Clonidine. Lomitapide The metabolism of Clonidine can be decreased when combined with Lomitapide. Lonafarnib The metabolism of Clonidine can be decreased when combined with Lonafarnib. Lonapegsomatropin The metabolism of Clonidine can be increased when combined with Lonapegsomatropin. Loperamide Clonidine may increase the bradycardic activities of Loperamide. Lopinavir The metabolism of Clonidine can be decreased when combined with Lopinavir. Lorazepam The risk or severity of sedation can be increased when Clonidine is combined with Lorazepam. Lorcaserin The risk or severity of sedation can be increased when Clonidine is combined with Lorcaserin. Lorlatinib The metabolism of Clonidine can be increased when combined with Lorlatinib. Lormetazepam The risk or severity of sedation can be increased when Clonidine is combined with Lormetazepam. Lornoxicam The therapeutic efficacy of Clonidine can be decreased when used in combination with Lornoxicam. Lorpiprazole The metabolism of Clonidine can be decreased when combined with Lorpiprazole. Losartan The risk or severity of hypotension can be increased when Clonidine is combined with Losartan. Lovastatin The metabolism of Clonidine can be decreased when combined with Lovastatin. Loxapine The risk or severity of sedation can be increased when Clonidine is combined with Loxapine. Loxoprofen The therapeutic efficacy of Clonidine can be decreased when used in combination with Loxoprofen. Lucinactant Clonidine may increase the bradycardic activities of Lucinactant. Lumacaftor The serum concentration of Clonidine can be decreased when it is combined with Lumacaftor. Lumateperone The risk or severity of sedation can be increased when Clonidine is combined with Lumateperone. Lumefantrine The metabolism of Clonidine can be decreased when combined with Lumefantrine. Lumiracoxib The therapeutic efficacy of Clonidine can be decreased when used in combination with Lumiracoxib. Lurasidone The risk or severity of sedation can be increased when Clonidine is combined with Lurasidone. Lynestrenol The risk or severity of sedation can be increased when Lynestrenol is combined with Clonidine. Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Clonidine. Macitentan The risk or severity of hypotension can be increased when Clonidine is combined with Macitentan. Magnesium sulfate The risk or severity of sedation can be increased when Clonidine is combined with Magnesium sulfate. Manidipine The risk or severity of hypotension can be increased when Clonidine is combined with Manidipine. Mannitol The risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol. Maprotiline The risk or severity of sedation can be increased when Clonidine is combined with Maprotiline. Mavacamten The serum concentration of Clonidine can be decreased when it is combined with Mavacamten. Mazindol The risk or severity of sedation can be increased when Clonidine is combined with Mazindol. Mebeverine The risk or severity of Tachycardia can be increased when Clonidine is combined with Mebeverine. Mebutamate The risk or severity of sedation can be increased when Clonidine is combined with Mebutamate. Mecamylamine The risk or severity of hypotension can be increased when Clonidine is combined with Mecamylamine. Meclizine The risk or severity of sedation can be increased when Clonidine is combined with Meclizine. Meclofenamic acid The therapeutic efficacy of Clonidine can be decreased when used in combination with Meclofenamic acid. Medifoxamine The risk or severity of sedation can be increased when Clonidine is combined with Medifoxamine. Medroxyprogesterone acetate The risk or severity of sedation can be increased when Medroxyprogesterone acetate is combined with Clonidine. Mefenamic acid The therapeutic efficacy of Clonidine can be decreased when used in combination with Mefenamic acid. Megestrol acetate The risk or severity of sedation can be increased when Megestrol acetate is combined with Clonidine. Melatonin The risk or severity of sedation can be increased when Clonidine is combined with Melatonin. Meloxicam The therapeutic efficacy of Clonidine can be decreased when used in combination with Meloxicam. Menthyl salicylate The therapeutic efficacy of Clonidine can be decreased when used in combination with Menthyl salicylate. Mepenzolate The risk or severity of Tachycardia can be increased when Clonidine is combined with Mepenzolate. Meperidine The risk or severity of sedation can be increased when Clonidine is combined with Meperidine. Mephentermine Mephentermine may decrease the antihypertensive activities of Clonidine. Mephenytoin The risk or severity of sedation can be increased when Clonidine is combined with Mephenytoin. Mepivacaine The risk or severity of sedation can be increased when Clonidine is combined with Mepivacaine. Meprednisone The metabolism of Clonidine can be increased when combined with Meprednisone. Meprobamate The risk or severity of sedation can be increased when Clonidine is combined with Meprobamate. Mepyramine The risk or severity of sedation can be increased when Clonidine is combined with Mepyramine. Mesalazine Mesalazine may decrease the antihypertensive activities of Clonidine. Mesoridazine The risk or severity of sedation can be increased when Clonidine is combined with Mesoridazine. Mestranol The risk or severity of sedation can be increased when Mestranol is combined with Clonidine. Metamfetamine The metabolism of Clonidine can be decreased when combined with Metamfetamine. Metamizole Metamizole may decrease the antihypertensive activities of Clonidine. Metaraminol Metaraminol may decrease the antihypertensive activities of Clonidine. Metaxalone The risk or severity of sedation can be increased when Clonidine is combined with Metaxalone. Metergoline The risk or severity of sedation can be increased when Clonidine is combined with Metergoline. Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Clonidine. Methantheline The risk or severity of Tachycardia can be increased when Clonidine is combined with Methantheline. Methazolamide The risk or severity of adverse effects can be increased when Clonidine is combined with Methazolamide. Methimazole The metabolism of Clonidine can be decreased when combined with Methimazole. Methocarbamol The risk or severity of sedation can be increased when Clonidine is combined with Methocarbamol. Methohexital The risk or severity of sedation can be increased when Clonidine is combined with Methohexital. Methotrimeprazine The risk or severity of sedation can be increased when Clonidine is combined with Methotrimeprazine. Methoxamine Methoxamine may decrease the antihypertensive activities of Clonidine. Methoxsalen The metabolism of Clonidine can be decreased when combined with Methoxsalen. Methoxyflurane The risk or severity of sedation can be increased when Clonidine is combined with Methoxyflurane. Methoxyphenamine Methoxyphenamine may decrease the antihypertensive activities of Clonidine. Methscopolamine The risk or severity of Tachycardia can be increased when Clonidine is combined with Methscopolamine. Methscopolamine bromide The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Clonidine. Methsuximide The risk or severity of sedation can be increased when Clonidine is combined with Methsuximide. Methyldopa The risk or severity of hypotension can be increased when Clonidine is combined with Methyldopa. Methylene blue The risk or severity of sedation can be increased when Clonidine is combined with Methylene blue. Methylergometrine The serum concentration of Clonidine can be increased when it is combined with Methylergometrine. Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine. Methylphenobarbital The risk or severity of sedation can be increased when Clonidine is combined with Methylphenobarbital. Methylprednisolone The metabolism of Clonidine can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Clonidine can be decreased when combined with Methylprednisone. Methyprylon The risk or severity of sedation can be increased when Clonidine is combined with Methyprylon. Methysergide The risk or severity of sedation can be increased when Clonidine is combined with Methysergide. Metipranolol Clonidine may increase the hypotensive activities of Metipranolol. Metixene The risk or severity of Tachycardia can be increased when Metixene is combined with Clonidine. Metoclopramide The risk or severity of sedation can be increased when Metoclopramide is combined with Clonidine. Metocurine The risk or severity of sedation can be increased when Clonidine is combined with Metocurine. Metocurine iodide The risk or severity of sedation can be increased when Clonidine is combined with Metocurine iodide. Metolazone The risk or severity of hypotension can be increased when Clonidine is combined with Metolazone. Metoprolol The risk or severity of hypotension can be increased when Clonidine is combined with Metoprolol. Metreleptin The metabolism of Clonidine can be increased when combined with Metreleptin. Metronidazole The serum concentration of Clonidine can be increased when it is combined with Metronidazole. Metyrapone The metabolism of Clonidine can be increased when combined with Metyrapone. Metyrosine The risk or severity of hypotension can be increased when Clonidine is combined with Metyrosine. Mexiletine The metabolism of Clonidine can be decreased when combined with Mexiletine. Mianserin The risk or severity of sedation can be increased when Clonidine is combined with Mianserin. Miconazole The metabolism of Clonidine can be decreased when combined with Miconazole. Midazolam The risk or severity of sedation can be increased when Clonidine is combined with Midazolam. Midodrine Midodrine may decrease the antihypertensive activities of Clonidine. Midostaurin The metabolism of Clonidine can be decreased when combined with Midostaurin. Mifepristone The risk or severity of sedation can be increased when Mifepristone is combined with Clonidine. Milnacipran The risk or severity of sedation can be increased when Clonidine is combined with Milnacipran. Minaprine The risk or severity of sedation can be increased when Clonidine is combined with Minaprine. Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine. Minoxidil The risk or severity of hypotension can be increased when Clonidine is combined with Minoxidil. Miocamycin The serum concentration of Clonidine can be increased when it is combined with Miocamycin. Mirabegron The serum concentration of Clonidine can be increased when it is combined with Mirabegron. Mirtazapine The risk or severity of sedation can be increased when Clonidine is combined with Mirtazapine. Mitapivat The metabolism of Clonidine can be increased when combined with Mitapivat. Mitotane The metabolism of Clonidine can be increased when combined with Mitotane. Mivacurium The risk or severity of sedation can be increased when Clonidine is combined with Mivacurium. Mobocertinib The serum concentration of Clonidine can be decreased when it is combined with Mobocertinib. Moclobemide The risk or severity of sedation can be increased when Clonidine is combined with Moclobemide. Modafinil The metabolism of Clonidine can be increased when combined with Modafinil. Moexipril The risk or severity of hypotension can be increased when Clonidine is combined with Moexipril. Molindone The risk or severity of sedation can be increased when Clonidine is combined with Molindone. Molsidomine Molsidomine may increase the hypotensive activities of Clonidine. Mometasone furoate The metabolism of Clonidine can be increased when combined with Mometasone furoate. Moricizine The risk or severity of sedation can be increased when Clonidine is combined with Moricizine. Morphine The risk or severity of sedation can be increased when Clonidine is combined with Morphine. Mosunetuzumab The metabolism of Clonidine can be decreased when combined with Mosunetuzumab. Moxifloxacin The metabolism of Clonidine can be decreased when combined with Moxifloxacin. Moxisylyte Moxisylyte may decrease the antihypertensive activities of Clonidine. Moxonidine The risk or severity of hypotension can be increased when Clonidine is combined with Moxonidine. Muzolimine The risk or severity of hypotension can be increased when Clonidine is combined with Muzolimine. Mycophenolate mofetil The metabolism of Clonidine can be decreased when combined with Mycophenolate mofetil. Nabilone The risk or severity of sedation can be increased when Clonidine is combined with Nabilone. Nabumetone The therapeutic efficacy of Clonidine can be decreased when used in combination with Nabumetone. Nadolol The risk or severity of hypotension can be increased when Clonidine is combined with Nadolol. Nafcillin The metabolism of Clonidine can be increased when combined with Nafcillin. Nalbuphine The risk or severity of sedation can be increased when Clonidine is combined with Nalbuphine. Nalidixic acid The metabolism of Clonidine can be decreased when combined with Nalidixic acid. Naloxegol The risk or severity of hypotension can be increased when Naloxegol is combined with Clonidine. Naltrexone The risk or severity of hypotension can be increased when Naltrexone is combined with Clonidine. Naphazoline Naphazoline may decrease the antihypertensive activities of Clonidine. Naproxen The therapeutic efficacy of Clonidine can be decreased when used in combination with Naproxen. Naratriptan The risk or severity of sedation can be increased when Clonidine is combined with Naratriptan. Nateglinide The metabolism of Clonidine can be decreased when combined with Nateglinide. Naxitamab Naxitamab may decrease the antihypertensive activities of Clonidine. Nebivolol The risk or severity of hypotension can be increased when Clonidine is combined with Nebivolol. Nefazodone The risk or severity of sedation can be increased when Clonidine is combined with Nefazodone. Nelfinavir The metabolism of Clonidine can be decreased when combined with Nelfinavir. Nesiritide The risk or severity of adverse effects can be increased when Clonidine is combined with Nesiritide. Netupitant The metabolism of Clonidine can be decreased when combined with Netupitant. Nevirapine The metabolism of Clonidine can be decreased when combined with Nevirapine. Niacin The serum concentration of Clonidine can be increased when it is combined with Niacin. Nialamide The risk or severity of sedation can be increased when Clonidine is combined with Nialamide. Nicardipine The risk or severity of hypotension can be increased when Clonidine is combined with Nicardipine. Nicergoline The metabolism of Clonidine can be decreased when combined with Nicergoline. Niclosamide The metabolism of Clonidine can be decreased when combined with Niclosamide. Nicorandil The risk or severity of hypotension can be increased when Clonidine is combined with Nicorandil. Nicotine The risk or severity of Tachycardia can be increased when Nicotine is combined with Clonidine. Nifedipine Clonidine may increase the atrioventricular blocking (AV block) activities of Nifedipine. Nilotinib The metabolism of Clonidine can be decreased when combined with Nilotinib. Nilvadipine The risk or severity of hypotension can be increased when Clonidine is combined with Nilvadipine. Nimesulide Clonidine may increase the atrioventricular blocking (AV block) activities of Nimesulide. Nimodipine The risk or severity of hypotension can be increased when Clonidine is combined with Nimodipine. Nintedanib The metabolism of Clonidine can be decreased when combined with Nintedanib. Nirogacestat The metabolism of Clonidine can be decreased when combined with Nirogacestat. Nisoldipine The risk or severity of hypotension can be increased when Clonidine is combined with Nisoldipine. Nitrazepam The risk or severity of sedation can be increased when Clonidine is combined with Nitrazepam. Nitrendipine The risk or severity of hypotension can be increased when Clonidine is combined with Nitrendipine. Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clonidine. Nitroglycerin The risk or severity of hypotension can be increased when Clonidine is combined with Nitroglycerin. Nitroprusside The risk or severity of hypotension can be increased when Clonidine is combined with Nitroprusside. Nitrous acid The risk or severity of adverse effects can be increased when Clonidine is combined with Nitrous acid. Nitrous oxide The risk or severity of sedation can be increased when Clonidine is combined with Nitrous oxide. Nomegestrol acetate The risk or severity of sedation can be increased when Nomegestrol acetate is combined with Clonidine. Nomifensine The risk or severity of sedation can be increased when Clonidine is combined with Nomifensine. Norepinephrine Norepinephrine may decrease the antihypertensive activities of Clonidine. Norethisterone The risk or severity of sedation can be increased when Norethisterone is combined with Clonidine. Norethynodrel The risk or severity of sedation can be increased when Norethynodrel is combined with Clonidine. Norfloxacin The metabolism of Clonidine can be decreased when combined with Norfloxacin. Norgestimate The risk or severity of sedation can be increased when Norgestimate is combined with Clonidine. Norgestrel The risk or severity of sedation can be increased when Norgestrel is combined with Clonidine. Normethadone The risk or severity of sedation can be increased when Clonidine is combined with Normethadone. Nortriptyline The risk or severity of sedation can be increased when Clonidine is combined with Nortriptyline. Noscapine The serum concentration of Clonidine can be increased when it is combined with Noscapine. Nylidrin Clonidine may increase the atrioventricular blocking (AV block) activities of Nylidrin. Obeticholic acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Clonidine. Obinutuzumab Clonidine may increase the hypotensive activities of Obinutuzumab. Octreotide The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Clonidine. Olanzapine The risk or severity of sedation can be increased when Clonidine is combined with Olanzapine. Olaparib The metabolism of Clonidine can be decreased when combined with Olaparib. Oliceridine The risk or severity of sedation can be increased when Clonidine is combined with Oliceridine. Olmesartan The risk or severity of hypotension can be increased when Clonidine is combined with Olmesartan. Olodaterol Olodaterol may decrease the antihypertensive activities of Clonidine. Olutasidenib The metabolism of Clonidine can be increased when combined with Olutasidenib. Omaveloxolone The serum concentration of Clonidine can be decreased when it is combined with Omaveloxolone. Ondansetron The risk or severity of sedation can be increased when Clonidine is combined with Ondansetron. Opicapone The risk or severity of adverse effects can be increased when Clonidine is combined with Opicapone. Opium The risk or severity of sedation can be increased when Clonidine is combined with Opium. Orciprenaline Orciprenaline may decrease the antihypertensive activities of Clonidine. Oritavancin The metabolism of Clonidine can be increased when combined with Oritavancin. Orphenadrine The risk or severity of sedation can be increased when Clonidine is combined with Orphenadrine. Osilodrostat The serum concentration of Clonidine can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Clonidine can be decreased when it is combined with Osimertinib. Ospemifene The metabolism of Clonidine can be decreased when combined with Ospemifene. Ouabain Clonidine may increase the atrioventricular blocking (AV block) activities of Ouabain. Oxamniquine The metabolism of Clonidine can be decreased when combined with Oxamniquine. Oxaprozin The therapeutic efficacy of Clonidine can be decreased when used in combination with Oxaprozin. Oxazepam The risk or severity of sedation can be increased when Clonidine is combined with Oxazepam. Oxcarbazepine The risk or severity of sedation can be increased when Clonidine is combined with Oxcarbazepine. Oxitriptan The risk or severity of sedation can be increased when Clonidine is combined with Oxitriptan. Oxprenolol The risk or severity of sedation can be increased when Clonidine is combined with Oxprenolol. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Clonidine. Oxybuprocaine The risk or severity of sedation can be increased when Clonidine is combined with Oxybuprocaine. Oxybutynin The serum concentration of Clonidine can be increased when it is combined with Oxybutynin. Oxycodone The risk or severity of sedation can be increased when Clonidine is combined with Oxycodone. Oxymetazoline The therapeutic efficacy of Clonidine can be decreased when used in combination with Oxymetazoline. Oxymorphone The risk or severity of sedation can be increased when Clonidine is combined with Oxymorphone. Oxyphenbutazone The therapeutic efficacy of Clonidine can be decreased when used in combination with Oxyphenbutazone. Oxyphencyclimine The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Clonidine. Oxyphenonium The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Clonidine. Paclitaxel The metabolism of Clonidine can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Clonidine can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Clonidine can be decreased when combined with Palbociclib. Paliperidone The risk or severity of sedation can be increased when Clonidine is combined with Paliperidone. Palonosetron The risk or severity of sedation can be increased when Clonidine is combined with Palonosetron. Palovarotene The metabolism of Clonidine can be increased when combined with Palovarotene. Pancuronium The risk or severity of sedation can be increased when Clonidine is combined with Pancuronium. Panobinostat The metabolism of Clonidine can be decreased when combined with Panobinostat. Papaverine The risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine. Paraldehyde The risk or severity of sedation can be increased when Clonidine is combined with Paraldehyde. Paramethadione The risk or severity of sedation can be increased when Clonidine is combined with Paramethadione. Parecoxib The therapeutic efficacy of Clonidine can be decreased when used in combination with Parecoxib. Pargyline The risk or severity of sedation can be increased when Clonidine is combined with Pargyline. Paritaprevir The metabolism of Clonidine can be decreased when combined with Paritaprevir. Paroxetine The risk or severity of sedation can be increased when Clonidine is combined with Paroxetine. Pasireotide The metabolism of Clonidine can be decreased when combined with Pasireotide. Pazopanib The metabolism of Clonidine can be decreased when combined with Pazopanib. Pefloxacin The metabolism of Clonidine can be decreased when combined with Pefloxacin. Peginterferon alfa-2a The metabolism of Clonidine can be decreased when combined with Peginterferon alfa-2a. Peginterferon alfa-2b The serum concentration of Clonidine can be increased when it is combined with Peginterferon alfa-2b. Pemetrexed The metabolism of Pemetrexed can be decreased when combined with Clonidine. Penbutolol The risk or severity of sedation can be increased when Clonidine is combined with Penbutolol. Penciclovir The metabolism of Clonidine can be decreased when combined with Penciclovir. Pentamidine The metabolism of Clonidine can be decreased when combined with Pentamidine. Pentazocine The risk or severity of sedation can be increased when Clonidine is combined with Pentazocine. Pentobarbital The risk or severity of sedation can be increased when Clonidine is combined with Pentobarbital. Pentolinium The risk or severity of hypotension can be increased when Clonidine is combined with Pentolinium. Pentoxifylline Pentoxifylline may increase the hypotensive activities of Clonidine. Perampanel The risk or severity of sedation can be increased when Clonidine is combined with Perampanel. Perazine The risk or severity of sedation can be increased when Clonidine is combined with Perazine. Pergolide The risk or severity of sedation can be increased when Clonidine is combined with Pergolide. Perhexiline Clonidine may increase the atrioventricular blocking (AV block) activities of Perhexiline. Periciazine The risk or severity of sedation can be increased when Clonidine is combined with Periciazine. Perindopril The risk or severity of hypotension can be increased when Clonidine is combined with Perindopril. Perphenazine The risk or severity of sedation can be increased when Clonidine is combined with Perphenazine. Phenacemide The risk or severity of sedation can be increased when Clonidine is combined with Phenacemide. Phendimetrazine Phendimetrazine may decrease the antihypertensive activities of Clonidine. Phenelzine The risk or severity of sedation can be increased when Clonidine is combined with Phenelzine. Phenformin The metabolism of Clonidine can be decreased when combined with Phenformin. Phenmetrazine Phenmetrazine may decrease the antihypertensive activities of Clonidine. Phenobarbital The risk or severity of sedation can be increased when Clonidine is combined with Phenobarbital. Phenoxybenzamine The risk or severity of hypotension can be increased when Clonidine is combined with Phenoxybenzamine. Phensuximide The risk or severity of sedation can be increased when Clonidine is combined with Phensuximide. Phentermine Phentermine may decrease the antihypertensive activities of Clonidine. Phentolamine The risk or severity of hypotension can be increased when Clonidine is combined with Phentolamine. Phenylbutazone The metabolism of Clonidine can be increased when combined with Phenylbutazone. Phenylbutyric acid The metabolism of Clonidine can be decreased when combined with Phenylbutyric acid. Phenylephrine The metabolism of Clonidine can be increased when combined with Phenylephrine. Phenylpropanolamine Phenylpropanolamine may decrease the antihypertensive activities of Clonidine. Phenytoin The risk or severity of sedation can be increased when Clonidine is combined with Phenytoin. Pimavanserin The metabolism of Clonidine can be decreased when combined with Pimavanserin. Pimozide The risk or severity of sedation can be increased when Clonidine is combined with Pimozide. Pinacidil The risk or severity of hypotension can be increased when Clonidine is combined with Pinacidil. Pinaverium Clonidine may increase the atrioventricular blocking (AV block) activities of Pinaverium. Pindolol The risk or severity of sedation can be increased when Clonidine is combined with Pindolol. Pipecuronium The risk or severity of sedation can be increased when Clonidine is combined with Pipecuronium. Piperaquine The metabolism of Clonidine can be decreased when combined with Piperaquine. Piperazine The metabolism of Clonidine can be decreased when combined with Piperazine. Pipotiazine The risk or severity of sedation can be increased when Clonidine is combined with Pipotiazine. Pirbuterol Pirbuterol may decrease the antihypertensive activities of Clonidine. Pirenzepine The risk or severity of Tachycardia can be increased when Clonidine is combined with Pirenzepine. Pirfenidone The metabolism of Clonidine can be decreased when combined with Pirfenidone. Piritramide The risk or severity of sedation can be increased when Clonidine is combined with Piritramide. Piroxicam The therapeutic efficacy of Clonidine can be decreased when used in combination with Piroxicam. Pirtobrutinib The metabolism of Clonidine can be decreased when combined with Pirtobrutinib. Pitolisant The serum concentration of Clonidine can be decreased when it is combined with Pitolisant. Pizotifen The risk or severity of sedation can be increased when Clonidine is combined with Pizotifen. Polythiazide The risk or severity of hypotension can be increased when Clonidine is combined with Polythiazide. Pomalidomide The risk or severity of sedation can be increased when Clonidine is combined with Pomalidomide. Ponatinib The metabolism of Ponatinib can be decreased when combined with Clonidine. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Clonidine. Poractant alfa Clonidine may increase the bradycardic activities of Poractant alfa. Posaconazole The metabolism of Clonidine can be decreased when combined with Posaconazole. Practolol The risk or severity of hypotension can be increased when Clonidine is combined with Practolol. Pralsetinib The metabolism of Clonidine can be increased when combined with Pralsetinib. Pramipexole Clonidine may increase the sedative activities of Pramipexole. Pramocaine The risk or severity of sedation can be increased when Clonidine is combined with Pramocaine. Prazepam The risk or severity of sedation can be increased when Clonidine is combined with Prazepam. Praziquantel The metabolism of Clonidine can be decreased when combined with Praziquantel. Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Clonidine. Prednisolone The metabolism of Clonidine can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Clonidine can be increased when combined with Prednisolone acetate. Prednisolone phosphate The metabolism of Clonidine can be increased when combined with Prednisolone phosphate. Prednisone acetate The metabolism of Clonidine can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of sedation can be increased when Clonidine is combined with Pregabalin. Prenylamine Clonidine may increase the atrioventricular blocking (AV block) activities of Prenylamine. Pretomanid The metabolism of Clonidine can be decreased when combined with Pretomanid. Prilocaine The risk or severity of sedation can be increased when Clonidine is combined with Prilocaine. Primaquine The metabolism of Clonidine can be decreased when combined with Primaquine. Primidone The risk or severity of sedation can be increased when Clonidine is combined with Primidone. Probenecid The metabolism of Clonidine can be increased when combined with Probenecid. Procainamide The metabolism of Procainamide can be decreased when combined with Clonidine. Procaine The risk or severity of sedation can be increased when Clonidine is combined with Procaine. Procarbazine The risk or severity of sedation can be increased when Clonidine is combined with Procarbazine. Procaterol Procaterol may decrease the antihypertensive activities of Clonidine. Prochlorperazine The risk or severity of sedation can be increased when Clonidine is combined with Prochlorperazine. Procyclidine The risk or severity of Tachycardia can be increased when Procyclidine is combined with Clonidine. Profenamine The therapeutic efficacy of Clonidine can be decreased when used in combination with Profenamine. Progesterone The metabolism of Clonidine can be decreased when combined with Progesterone. Proguanil The metabolism of Clonidine can be decreased when combined with Proguanil. Promazine The risk or severity of sedation can be increased when Clonidine is combined with Promazine. Promethazine The risk or severity of sedation can be increased when Clonidine is combined with Promethazine. Propafenone The metabolism of Clonidine can be decreased when combined with Propafenone. Propantheline The risk or severity of Tachycardia can be increased when Clonidine is combined with Propantheline. Propiomazine The risk or severity of sedation can be increased when Clonidine is combined with Propiomazine. Propiverine The therapeutic efficacy of Clonidine can be decreased when used in combination with Propiverine. Propofol The risk or severity of sedation can be increased when Clonidine is combined with Propofol. Propranolol The risk or severity of hypotension can be increased when Clonidine is combined with Propranolol. Protokylol The risk or severity of Tachycardia can be increased when Clonidine is combined with Protokylol. Protriptyline The risk or severity of sedation can be increased when Clonidine is combined with Protriptyline. Proxibarbal The risk or severity of sedation can be increased when Clonidine is combined with Proxibarbal. Pseudoephedrine Pseudoephedrine may decrease the antihypertensive activities of Clonidine. Pyrantel The risk or severity of sedation can be increased when Clonidine is combined with Pyrantel. Quazepam The risk or severity of sedation can be increased when Clonidine is combined with Quazepam. Quetiapine The risk or severity of sedation can be increased when Clonidine is combined with Quetiapine. Quinapril The risk or severity of hypotension can be increased when Clonidine is combined with Quinapril. Quinidine The metabolism of Clonidine can be decreased when combined with Quinidine. Quinine The risk or severity of sedation can be increased when Clonidine is combined with Quinine. Quinupramine The risk or severity of sedation can be increased when Clonidine is combined with Quinupramine. Quinupristin The metabolism of Clonidine can be decreased when combined with Quinupristin. Quizartinib The metabolism of Clonidine can be decreased when combined with Quizartinib. Racepinephrine Racepinephrine may decrease the antihypertensive activities of Clonidine. Raloxifene The serum concentration of Clonidine can be increased when it is combined with Raloxifene. Ramelteon The risk or severity of sedation can be increased when Clonidine is combined with Ramelteon. Ramipril The risk or severity of hypotension can be increased when Clonidine is combined with Ramipril. Ranitidine The metabolism of Clonidine can be decreased when combined with Ranitidine. Ranolazine The serum concentration of Clonidine can be increased when it is combined with Ranolazine. Rapacuronium The risk or severity of sedation can be increased when Clonidine is combined with Rapacuronium. Rasagiline The risk or severity of sedation can be increased when Clonidine is combined with Rasagiline. Reboxetine The risk or severity of sedation can be increased when Clonidine is combined with Reboxetine. Regorafenib Clonidine may increase the bradycardic activities of Regorafenib. Relugolix The metabolism of Clonidine can be decreased when combined with Relugolix. Remdesivir The metabolism of Clonidine can be decreased when combined with Remdesivir. Remifentanil The risk or severity of sedation can be increased when Clonidine is combined with Remifentanil. Remimazolam The risk or severity of sedation can be increased when Clonidine is combined with Remimazolam. Remoxipride The risk or severity of sedation can be increased when Clonidine is combined with Remoxipride. Repotrectinib The serum concentration of Clonidine can be decreased when it is combined with Repotrectinib. Rescinnamine The risk or severity of hypotension can be increased when Clonidine is combined with Rescinnamine. Reserpine The risk or severity of sedation can be increased when Clonidine is combined with Reserpine. Revefenacin The metabolism of Clonidine can be decreased when combined with Revefenacin. Ribociclib The metabolism of Clonidine can be decreased when combined with Ribociclib. Rifabutin The metabolism of Clonidine can be increased when combined with Rifabutin. Rifampicin The metabolism of Clonidine can be increased when combined with Rifampicin. Rifamycin The metabolism of Clonidine can be increased when combined with Rifamycin. Rifapentine The metabolism of Clonidine can be increased when combined with Rifapentine. Rilmenidine The risk or severity of hypotension can be increased when Clonidine is combined with Rilmenidine. Rilonacept The metabolism of Clonidine can be increased when combined with Rilonacept. Rilpivirine The metabolism of Clonidine can be decreased when combined with Rilpivirine. Riluzole The risk or severity of sedation can be increased when Clonidine is combined with Riluzole. Rimonabant The risk or severity of adverse effects can be increased when Rimonabant is combined with Clonidine. Riociguat The risk or severity of hypotension can be increased when Clonidine is combined with Riociguat. Risperidone The risk or severity of sedation can be increased when Clonidine is combined with Risperidone. Ritlecitinib The serum concentration of Clonidine can be increased when it is combined with Ritlecitinib. Ritodrine Ritodrine may decrease the antihypertensive activities of Clonidine. Ritonavir The serum concentration of Clonidine can be increased when it is combined with Ritonavir. Rituximab Clonidine may increase the hypotensive activities of Rituximab. Rivaroxaban The metabolism of Clonidine can be decreased when combined with Rivaroxaban. Rivastigmine Clonidine may increase the bradycardic activities of Rivastigmine. Rizatriptan Rizatriptan may decrease the antihypertensive activities of Clonidine. Rocuronium The risk or severity of sedation can be increased when Clonidine is combined with Rocuronium. Rofecoxib The metabolism of Clonidine can be increased when combined with Rofecoxib. Roflumilast The metabolism of Clonidine can be decreased when combined with Roflumilast. Rolapitant The metabolism of Clonidine can be decreased when combined with Rolapitant. Romidepsin The metabolism of Clonidine can be decreased when combined with Romidepsin. Ropeginterferon alfa-2b The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Clonidine. Ropinirole Clonidine may increase the sedative activities of Ropinirole. Ropivacaine The risk or severity of sedation can be increased when Clonidine is combined with Ropivacaine. Rosoxacin The metabolism of Clonidine can be decreased when combined with Rosoxacin. Rosuvastatin The metabolism of Clonidine can be decreased when combined with Rosuvastatin. Rotigotine The risk or severity of sedation can be increased when Clonidine is combined with Rotigotine. Roxithromycin The metabolism of Clonidine can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Clonidine can be decreased when combined with Rucaparib. Rufinamide The risk or severity of sedation can be increased when Clonidine is combined with Rufinamide. Rupatadine The metabolism of Clonidine can be decreased when combined with Rupatadine. Ruxolitinib Ruxolitinib may increase the bradycardic activities of Clonidine. Sacubitril The risk or severity of adverse effects can be increased when Clonidine is combined with Sacubitril. Safinamide The risk or severity of sedation can be increased when Clonidine is combined with Safinamide. Salicylamide The therapeutic efficacy of Clonidine can be decreased when used in combination with Salicylamide. Salicylic acid The therapeutic efficacy of Clonidine can be decreased when used in combination with Salicylic acid. Salmeterol The metabolism of Clonidine can be decreased when combined with Salmeterol. Salsalate The therapeutic efficacy of Clonidine can be decreased when used in combination with Salsalate. Samidorphan The risk or severity of sedation can be increased when Clonidine is combined with Samidorphan. Saquinavir The metabolism of Clonidine can be decreased when combined with Saquinavir. Sarilumab The metabolism of Clonidine can be increased when combined with Sarilumab. Satralizumab The serum concentration of Clonidine can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Clonidine can be decreased when combined with Saxagliptin. Scopolamine The risk or severity of sedation can be increased when Clonidine is combined with Scopolamine. Secobarbital The risk or severity of sedation can be increased when Clonidine is combined with Secobarbital. Secukinumab The metabolism of Clonidine can be increased when combined with Secukinumab. Selegiline The risk or severity of sedation can be increased when Clonidine is combined with Selegiline. Selexipag The risk or severity of hypotension can be increased when Clonidine is combined with Selexipag. Selpercatinib Selpercatinib may decrease the antihypertensive activities of Clonidine. Selumetinib The metabolism of Clonidine can be decreased when combined with Selumetinib. Serdexmethylphenidate The therapeutic efficacy of Clonidine can be decreased when used in combination with Serdexmethylphenidate. Sertindole The risk or severity of sedation can be increased when Clonidine is combined with Sertindole. Sertraline The risk or severity of sedation can be increased when Clonidine is combined with Sertraline. Sevoflurane The risk or severity of sedation can be increased when Clonidine is combined with Sevoflurane. Sibutramine The risk or severity of sedation can be increased when Clonidine is combined with Sibutramine. Sildenafil The metabolism of Clonidine can be decreased when combined with Sildenafil. Silodosin The risk or severity of orthostatic hypotension and dizziness can be increased when Clonidine is combined with Silodosin. Siltuximab The metabolism of Clonidine can be increased when combined with Siltuximab. Simeprevir The metabolism of Clonidine can be decreased when combined with Simeprevir. Simvastatin The metabolism of Clonidine can be decreased when combined with Simvastatin. Siponimod The metabolism of Clonidine can be decreased when combined with Siponimod. Sirolimus The metabolism of Sirolimus can be decreased when combined with Clonidine. Sitaxentan The risk or severity of hypotension can be increased when Clonidine is combined with Sitaxentan. Sodium ferric gluconate complex The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Clonidine. Sodium oxybate Clonidine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Solifenacin The metabolism of Clonidine can be decreased when combined with Solifenacin. Solriamfetol The risk or severity of sedation can be increased when Clonidine is combined with Solriamfetol. Somapacitan The metabolism of Clonidine can be increased when combined with Somapacitan. Somatostatin The metabolism of Clonidine can be decreased when combined with Somatostatin. Somatotropin The metabolism of Clonidine can be increased when combined with Somatotropin. Somatrem The metabolism of Clonidine can be increased when combined with Somatrem. Somatrogon The metabolism of Clonidine can be increased when combined with Somatrogon. Sorafenib The metabolism of Clonidine can be decreased when combined with Sorafenib. Sotalol The risk or severity of bradycardia can be increased when Clonidine is combined with Sotalol. Sotorasib The serum concentration of Clonidine can be decreased when it is combined with Sotorasib. Spirapril The risk or severity of hypotension can be increased when Clonidine is combined with Spirapril. Spironolactone The risk or severity of hypotension can be increased when Clonidine is combined with Spironolactone. St. John's Wort The risk or severity of sedation can be increased when Clonidine is combined with St. John's Wort. Stiripentol The risk or severity of sedation can be increased when Clonidine is combined with Stiripentol. Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine. Succinylcholine The risk or severity of sedation can be increased when Clonidine is combined with Succinylcholine. Sufentanil The risk or severity of sedation can be increased when Clonidine is combined with Sufentanil. Sulfamethoxazole The serum concentration of Clonidine can be increased when it is combined with Sulfamethoxazole. Sulfaphenazole The metabolism of Clonidine can be decreased when combined with Sulfaphenazole. Sulfasalazine The therapeutic efficacy of Clonidine can be decreased when used in combination with Sulfasalazine. Sulfinpyrazone The metabolism of Clonidine can be increased when combined with Sulfinpyrazone. Sulindac The therapeutic efficacy of Clonidine can be decreased when used in combination with Sulindac. Sulpiride The risk or severity of sedation can be increased when Clonidine is combined with Sulpiride. Sulthiame The risk or severity of sedation can be increased when Clonidine is combined with Sulthiame. Sultopride The risk or severity of sedation can be increased when Clonidine is combined with Sultopride. Sumatriptan The risk or severity of sedation can be increased when Clonidine is combined with Sumatriptan. Sunitinib The metabolism of Sunitinib can be decreased when combined with Clonidine. Suvorexant The risk or severity of sedation can be increased when Clonidine is combined with Suvorexant. Tacrine The metabolism of Clonidine can be decreased when combined with Tacrine. Tacrolimus The metabolism of Clonidine can be decreased when combined with Tacrolimus. Tadalafil The risk or severity of hypotension can be increased when Clonidine is combined with Tadalafil. Tafenoquine The metabolism of Clonidine can be decreased when combined with Tafenoquine. Talbutal The risk or severity of sedation can be increased when Clonidine is combined with Talbutal. Tamoxifen The metabolism of Clonidine can be increased when combined with Tamoxifen. Tamsulosin The metabolism of Clonidine can be decreased when combined with Tamsulosin. Tapentadol The risk or severity of sedation can be increased when Clonidine is combined with Tapentadol. Tasimelteon The risk or severity of sedation can be increased when Clonidine is combined with Tasimelteon. Tazemetostat The metabolism of Clonidine can be decreased when combined with Tazemetostat. Tecovirimat The metabolism of Clonidine can be increased when combined with Tecovirimat. Tegafur The metabolism of Tegafur can be decreased when combined with Clonidine. Tegaserod The metabolism of Clonidine can be decreased when combined with Tegaserod. Telaprevir The metabolism of Clonidine can be decreased when combined with Telaprevir. Telithromycin The metabolism of Clonidine can be decreased when combined with Telithromycin. Telmisartan The risk or severity of hypotension can be increased when Clonidine is combined with Telmisartan. Telotristat ethyl The serum concentration of Clonidine can be decreased when it is combined with Telotristat ethyl. Temazepam The risk or severity of sedation can be increased when Clonidine is combined with Temazepam. Temsirolimus The metabolism of Clonidine can be decreased when combined with Temsirolimus. Teniposide The serum concentration of Clonidine can be increased when it is combined with Teniposide. Tenofovir alafenamide The metabolism of Clonidine can be decreased when combined with Tenofovir alafenamide. Tenoxicam The therapeutic efficacy of Clonidine can be decreased when used in combination with Tenoxicam. Terazosin The risk or severity of hypotension can be increased when Clonidine is combined with Terazosin. Terbinafine The metabolism of Clonidine can be decreased when combined with Terbinafine. Terbutaline Terbutaline may decrease the antihypertensive activities of Clonidine. Terfenadine The metabolism of Clonidine can be decreased when combined with Terfenadine. Teriflunomide The serum concentration of Clonidine can be decreased when it is combined with Teriflunomide. Testosterone The metabolism of Clonidine can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Clonidine can be decreased when combined with Testosterone cypionate. Testosterone enanthate The metabolism of Clonidine can be decreased when combined with Testosterone enanthate. Testosterone undecanoate Testosterone undecanoate may increase the hypertensive activities of Clonidine. Tetrabenazine The metabolism of Clonidine can be decreased when combined with Tetrabenazine. Tetracaine The risk or severity of sedation can be increased when Clonidine is combined with Tetracaine. Tetracycline The serum concentration of Clonidine can be increased when it is combined with Tetracycline. Tetryzoline Tetryzoline may decrease the antihypertensive activities of Clonidine. Tezacaftor The metabolism of Clonidine can be decreased when combined with Tezacaftor. Thalidomide Clonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Theophylline The metabolism of Clonidine can be decreased when combined with Theophylline. Thiabendazole The metabolism of Clonidine can be decreased when combined with Thiabendazole. Thiamylal The risk or severity of sedation can be increased when Clonidine is combined with Thiamylal. Thiethylperazine The risk or severity of sedation can be increased when Clonidine is combined with Thiethylperazine. Thiopental The risk or severity of sedation can be increased when Clonidine is combined with Thiopental. Thioridazine The risk or severity of sedation can be increased when Clonidine is combined with Thioridazine. Thiothixene The risk or severity of sedation can be increased when Clonidine is combined with Thiothixene. Thonzylamine The risk or severity of Tachycardia can be increased when Clonidine is combined with Thonzylamine. Tiagabine The risk or severity of sedation can be increased when Clonidine is combined with Tiagabine. Tiaprofenic acid The therapeutic efficacy of Clonidine can be decreased when used in combination with Tiaprofenic acid. Ticagrelor The metabolism of Clonidine can be decreased when combined with Ticagrelor. Ticlopidine The metabolism of Clonidine can be decreased when combined with Ticlopidine. Timolol Timolol may increase the hypertensive activities of Clonidine. Tiotropium The metabolism of Clonidine can be decreased when combined with Tiotropium. Tipranavir The metabolism of Clonidine can be decreased when combined with Tipranavir. Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Clonidine. Tocainide The metabolism of Clonidine can be decreased when combined with Tocainide. Tocilizumab The metabolism of Clonidine can be increased when combined with Tocilizumab. Tofacitinib Clonidine may increase the bradycardic activities of Tofacitinib. Tolazoline The risk or severity of hypotension can be increased when Clonidine is combined with Tolazoline. Tolcapone The risk or severity of sedation can be increased when Clonidine is combined with Tolcapone. Tolfenamic acid The therapeutic efficacy of Clonidine can be decreased when used in combination with Tolfenamic acid. Tolmetin The therapeutic efficacy of Clonidine can be decreased when used in combination with Tolmetin. Tolterodine The metabolism of Clonidine can be decreased when combined with Tolterodine. Topiramate The risk or severity of sedation can be increased when Clonidine is combined with Topiramate. Torasemide The risk or severity of hypotension can be increased when Clonidine is combined with Torasemide. Tovorafenib The metabolism of Clonidine can be increased when combined with Tovorafenib. Trabectedin The metabolism of Trabectedin can be decreased when combined with Clonidine. Tramadol The risk or severity of sedation can be increased when Clonidine is combined with Tramadol. Trandolapril The risk or severity of hypotension can be increased when Clonidine is combined with Trandolapril. Tranylcypromine The risk or severity of sedation can be increased when Clonidine is combined with Tranylcypromine. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Clonidine. Trazodone The risk or severity of sedation can be increased when Clonidine is combined with Trazodone. Treprostinil The risk or severity of hypotension can be increased when Clonidine is combined with Treprostinil. Tretinoin The risk or severity of elevated intracranial pressure can be increased when Clonidine is combined with Tretinoin. Triamcinolone The metabolism of Clonidine can be increased when combined with Triamcinolone. Triamterene The metabolism of Clonidine can be decreased when combined with Triamterene. Triazolam The risk or severity of sedation can be increased when Clonidine is combined with Triazolam. Trichlormethiazide The risk or severity of hypotension can be increased when Clonidine is combined with Trichlormethiazide. Trichloroethylene The risk or severity of sedation can be increased when Clonidine is combined with Trichloroethylene. Triclabendazole The serum concentration of Clonidine can be increased when it is combined with Triclabendazole. Triclofos The risk or severity of sedation can be increased when Clonidine is combined with Triclofos. Trifluoperazine The risk or severity of sedation can be increased when Clonidine is combined with Trifluoperazine. Triflupromazine The risk or severity of sedation can be increased when Clonidine is combined with Triflupromazine. Trihexyphenidyl The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Clonidine. Trilaciclib The metabolism of Clonidine can be increased when combined with Trilaciclib. Trimebutine Clonidine may increase the atrioventricular blocking (AV block) activities of Trimebutine. Trimethadione The risk or severity of sedation can be increased when Clonidine is combined with Trimethadione. Trimethaphan The risk or severity of hypotension can be increased when Clonidine is combined with Trimethaphan. Trimethobenzamide The risk or severity of sedation can be increased when Clonidine is combined with Trimethobenzamide. Trimipramine The risk or severity of sedation can be increased when Clonidine is combined with Trimipramine. Tripelennamine The metabolism of Clonidine can be decreased when combined with Tripelennamine. Triprolidine The risk or severity of sedation can be increased when Clonidine is combined with Triprolidine. Trofinetide The metabolism of Clonidine can be decreased when combined with Trofinetide. Troglitazone The metabolism of Clonidine can be increased when combined with Troglitazone. Troleandomycin The metabolism of Clonidine can be decreased when combined with Troleandomycin. Tropisetron The risk or severity of sedation can be increased when Clonidine is combined with Tropisetron. Trospium The metabolism of Clonidine can be decreased when combined with Trospium. Trovafloxacin The metabolism of Clonidine can be decreased when combined with Trovafloxacin. Tryptophan The risk or severity of sedation can be increased when Clonidine is combined with Tryptophan. Tubocurarine The risk or severity of sedation can be increased when Clonidine is combined with Tubocurarine. Tucatinib The metabolism of Tucatinib can be decreased when combined with Clonidine. Udenafil The metabolism of Clonidine can be decreased when combined with Udenafil. Umeclidinium The metabolism of Clonidine can be decreased when combined with Umeclidinium. Unoprostone Clonidine may increase the hypotensive activities of Unoprostone. Urethane The risk or severity of sedation can be increased when Clonidine is combined with Urethane. Vadadustat The serum concentration of Clonidine can be increased when it is combined with Vadadustat. Valbenazine The metabolism of Clonidine can be decreased when combined with Valbenazine. Valdecoxib The therapeutic efficacy of Clonidine can be decreased when used in combination with Valdecoxib. Valproic acid The risk or severity of sedation can be increased when Clonidine is combined with Valproic acid. Valsartan The risk or severity of hypotension can be increased when Clonidine is combined with Valsartan. Vardenafil The metabolism of Clonidine can be decreased when combined with Vardenafil. Vecuronium The risk or severity of sedation can be increased when Clonidine is combined with Vecuronium. Vemurafenib The serum concentration of Clonidine can be increased when it is combined with Vemurafenib. Venetoclax The metabolism of Clonidine can be decreased when combined with Venetoclax. Venlafaxine The risk or severity of sedation can be increased when Clonidine is combined with Venlafaxine. Verapamil Verapamil may increase the atrioventricular blocking (AV block) activities of Clonidine. Vericiguat The risk or severity of adverse effects can be increased when Clonidine is combined with Vericiguat. Vernakalant The metabolism of Clonidine can be decreased when combined with Vernakalant. Vigabatrin The risk or severity of sedation can be increased when Clonidine is combined with Vigabatrin. Vilanterol Vilanterol may decrease the antihypertensive activities of Clonidine. Vilazodone The risk or severity of sedation can be increased when Clonidine is combined with Vilazodone. Viloxazine The risk or severity of sedation can be increased when Clonidine is combined with Viloxazine. Vinblastine The metabolism of Clonidine can be increased when combined with Vinblastine. Vincristine The metabolism of Clonidine can be decreased when combined with Vincristine. Vinorelbine The metabolism of Clonidine can be decreased when combined with Vinorelbine. Vitamin E The metabolism of Clonidine can be increased when combined with Vitamin E. Vonoprazan The metabolism of Clonidine can be decreased when combined with Vonoprazan. Vorapaxar The metabolism of Clonidine can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Clonidine can be decreased when combined with Voriconazole. Vortioxetine The risk or severity of sedation can be increased when Clonidine is combined with Vortioxetine. Voxelotor The serum concentration of Clonidine can be increased when it is combined with Voxelotor. Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Clonidine. Warfarin The metabolism of Clonidine can be increased when combined with Warfarin. Xamoterol Xamoterol may decrease the antihypertensive activities of Clonidine. Xylometazoline Clonidine may increase the atrioventricular blocking (AV block) activities of Xylometazoline. Yohimbine The risk or severity of sedation can be increased when Clonidine is combined with Yohimbine. Zafirlukast The serum concentration of Clonidine can be increased when it is combined with Zafirlukast. Zaleplon The risk or severity of sedation can be increased when Clonidine is combined with Zaleplon. Ziconotide The risk or severity of sedation can be increased when Clonidine is combined with Ziconotide. Zileuton The metabolism of Clonidine can be decreased when combined with Zileuton. Zimelidine The risk or severity of sedation can be increased when Clonidine is combined with Zimelidine. Ziprasidone The risk or severity of sedation can be increased when Clonidine is combined with Ziprasidone. Zofenopril The risk or severity of hypotension can be increased when Clonidine is combined with Zofenopril. Zolmitriptan The risk or severity of sedation can be increased when Clonidine is combined with Zolmitriptan. Zolpidem The risk or severity of sedation can be increased when Clonidine is combined with Zolpidem. Zonisamide The risk or severity of sedation can be increased when Clonidine is combined with Zonisamide. Zopiclone The risk or severity of sedation can be increased when Clonidine is combined with Zopiclone. Zotepine The risk or severity of sedation can be increased when Clonidine is combined with Zotepine. Zuclopenthixol The risk or severity of sedation can be increased when Clonidine is combined with Zuclopenthixol. Zuranolone The risk or severity of sedation can be increased when Clonidine is combined with Zuranolone. - Food Interactions
- Avoid alcohol.
- Take with or without food. The absorption is unaffected by food.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Clonidine hydrochloride W76I6XXF06 4205-91-8 ZNIFSRGNXRYGHF-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Catapresan (Boehringer Ingelheim) / Catapressan (Boehringer Ingelheim) / Catarpres-TTS / Dixarit (Boehringer Ingelheim) / Isoglaucon (Agepha) / Run Rui (Bausch & Lomb) / Velaril (Roemmers) / Winpress (Winston)
- Brand Name Prescription Products
- Generic Prescription Products
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clorpres Clonidine hydrochloride (0.2 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Pharmaceuticals 1998-03-13 2018-02-28 US Clorpres Clonidine hydrochloride (0.2 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Bertek Pharmaceuticals 2015-11-01 2015-11-19 US Clorpres Clonidine hydrochloride (0.1 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Pharmaceuticals 1998-03-13 2018-02-28 US Clorpres Clonidine hydrochloride (0.1 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Bertek Pharmaceuticals 2015-11-01 2015-11-19 US Clorpres Clonidine hydrochloride (0.2 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Physicians Total Care, Inc. 2005-04-15 2011-06-30 US Clorpres Clonidine hydrochloride (0.3 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Pharmaceuticals 1998-03-13 2018-02-28 US Clorpres Clonidine hydrochloride (0.3 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Mylan Bertek Pharmaceuticals 2015-11-01 2015-11-19 US Clorpres Clonidine hydrochloride (0.1 mg/1) + Chlorthalidone (15 mg/1) Tablet Oral Physicians Total Care, Inc. 2005-01-26 2011-06-30 US Combipres 0.1/15 Tab Clonidine hydrochloride (.1 mg) + Chlorthalidone (15 mg) Tablet Oral Boehringer Ingelheim (Canada) Ltd Ltee 1974-12-31 1997-08-14 Canada Kapvay Clonidine hydrochloride (0.1 mg/1) + Clonidine hydrochloride (0.2 mg/1) Kit Oral Shionogi 2010-12-09 2014-08-31 US Kapvay Clonidine hydrochloride (0.1 mg/1) + Clonidine hydrochloride (0.2 mg/1) Kit Oral Shionogi 2010-12-09 2014-08-31 US
Categories
- ATC Codes
- S01EA04 — Clonidine
- S01EA — Sympathomimetics in glaucoma therapy
- S01E — ANTIGLAUCOMA PREPARATIONS AND MIOTICS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- C02LC — Imidazoline receptor agonists in combination with diuretics
- C02L — ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
- C02 — ANTIHYPERTENSIVES
- C — CARDIOVASCULAR SYSTEM
- C02AC — Imidazoline receptor agonists
- C02A — ANTIADRENERGIC AGENTS, CENTRALLY ACTING
- C02 — ANTIHYPERTENSIVES
- C — CARDIOVASCULAR SYSTEM
- N02CX — Other antimigraine preparations
- N02C — ANTIMIGRAINE PREPARATIONS
- N02 — ANALGESICS
- N — NERVOUS SYSTEM
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-1 Receptor Agonists
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Analgesics
- Anesthetics
- Anesthetics, General
- Antiadrenergic Agents, Centrally Acting
- Antiglaucoma Preparations and Miotics
- Antihypertensive Agents
- Antihypertensive Agents Indicated for Hypertension
- Antimigraine Preparations
- Autonomic Agents
- Bradycardia-Causing Agents
- Cardiovascular Agents
- Central alpha-2 Adrenergic Agonist
- Central Alpha-agonists
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 Substrates
- Hypotensive Agents
- Imidazoles
- Imidazoline Receptor Agonists
- Imidazolines
- Narrow Therapeutic Index Drugs
- Nervous System
- Neurotransmitter Agents
- Ophthalmologicals
- Peripheral Nervous System Agents
- Sensory Organs
- Sensory System Agents
- Sympatholytics
- Sympathomimetics in Glaucoma Therapy
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Dichlorobenzenes
- Alternative Parents
- Aniline and substituted anilines / Aryl chlorides / Imidazolines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- 1,3-dichlorobenzene / 2-imidazoline / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Carboximidamide / Guanidine / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- clonidine (CHEBI:3757)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- MN3L5RMN02
- CAS number
- 4205-90-7
- InChI Key
- GJSURZIOUXUGAL-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
- IUPAC Name
- N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
- SMILES
- ClC1=CC=CC(Cl)=C1NC1=NCCN1
References
- Synthesis Reference
David R. Pierce, William D. Dean, Michael E. Deason, "Process for preparation of clonidine derivatives." U.S. Patent US5684156, issued October, 1968.
US5684156- General References
- Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. [Article]
- Khan ZP, Ferguson CN, Jones RM: alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999 Feb;54(2):146-65. doi: 10.1046/j.1365-2044.1999.00659.x. [Article]
- Sjoberg RJ, Simcic KJ, Kidd GS: The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med. 1992 Jun;152(6):1193-7. [Article]
- Sliwinska-Mosson M, Zielen I, Milnerowicz H: New trends in the treatment of nicotine addiction. Acta Pol Pharm. 2014 Jul-Aug;71(4):525-30. [Article]
- Fresquez-Chavez KR, Fogger S: Reduction of opiate withdrawal symptoms with use of clonidine in a county jail. J Correct Health Care. 2015 Jan;21(1):27-34. doi: 10.1177/1078345814557630. Epub 2014 Nov 26. [Article]
- Vasseur B, Dufour A, Houdas L, Goodwin H, Harries K, Emul NY, Hutchings S: Comparison of the Systemic and Local Pharmacokinetics of Clonidine Mucoadhesive Buccal Tablets with Reference Clonidine Oral Tablets in Healthy Volunteers: An Open-Label Randomised Cross-Over Trial. Adv Ther. 2017 Aug;34(8):2022-2032. doi: 10.1007/s12325-017-0585-9. Epub 2017 Jul 19. [Article]
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
- FDA Approved Drug Products: Catapres Clonidine Hydrochloride Oral Tablets [Link]
- FDA Approved Drug Products: Catapres Clonidine Transdermal System [Link]
- FDA Approved Drug Products: Duraclon Clonidine Hydrochloride Injection Solution [Link]
- FDA Approved Drug Products: Kapvay (clonidine hydrochloride) Oral Extended Release Tablets [Link]
- Cayman Chemicals: Clonidine MSDS [Link]
- External Links
- Human Metabolome Database
- HMDB0014714
- KEGG Drug
- D00281
- PubChem Compound
- 2803
- PubChem Substance
- 46508119
- ChemSpider
- 2701
- BindingDB
- 14062
- 2599
- ChEBI
- 46632
- ChEMBL
- CHEMBL134
- ZINC
- ZINC000000896484
- Therapeutic Targets Database
- DAP000231
- PharmGKB
- PA449051
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- CLU
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Clonidine
- PDB Entries
- 2pnc / 7aww
- MSDS
- Download (73.8 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Boehringer ingelheim
- Aveva drug delivery systems inc
- Mylan technologies inc
- Tris pharma inc
- Pharmaforce inc
- Bioniche pharma usa llc
- Actavis elizabeth llc
- American therapeutics inc
- Dava pharmaceuticals inc
- Duramed pharmaceuticals inc sub barr laboratories inc
- Impax laboratories inc
- Interpharm inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Par pharmaceutical inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Unichem laboratories ltd
- Vintage pharmaceuticals llc
- Warner chilcott div warner lambert co
- Watson laboratories inc
- Shionogi pharma inc
- Packagers
- AAIPharma Inc.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Alza Corp.
- American Regent
- Amerisource Health Services Corp.
- Apotheca Inc.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Bioniche Pharma
- Blenheim Pharmacal
- Boehringer Ingelheim Ltd.
- Bryant Ranch Prepack
- Cardinal Health
- Central Texas Community Health Centers
- Comprehensive Consultant Services Inc.
- Coupler Enterprises Inc.
- DAVA Pharmaceuticals
- Dept Health Central Pharmacy
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Global Pharmaceuticals
- Heartland Repack Services LLC
- Innoviant Pharmacy Inc.
- Lake Erie Medical and Surgical Supply
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mckesson Corp.
- Medisca Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mutual Pharmaceutical Co.
- Mylan
- Neighborcare Repackaging Inc.
- Neuman Distributors Inc.
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmaforce Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Qualitest
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Richmond Pharmacy
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Tya Pharmaceuticals
- UDL Laboratories
- Unichem Laboratories Ltd.
- United Research Laboratories Inc.
- Vangard Labs Inc.
- Vintage Pharmaceuticals Inc.
- West-Ward Pharmaceuticals
- Xanodyne Pharmaceuticals Inc.
- Dosage Forms
Form Route Strength Injection Patch, extended release Transdermal 0.1 mg/24h Patch, extended release Transdermal 0.2 mg/24h Patch, extended release Transdermal 0.3 mg/24h Tablet Oral .300 mg/1 Tablet Oral 0.075 MG Capsule 0.25 MG Injection, solution 150 MICROGRAMMI/ML Tablet Oral 150 MICROGRAMMI Tablet Oral 300 MICROGRAMMI Injection, solution Parenteral 0.15 mg/ml Tablet Oral 0.15 mg/1 Tablet Oral 0.075 mg/1 Patch Transdermal 2.5 mg Patch Transdermal 5 mg Patch Transdermal 7.5 mg Tablet Oral 300 UG Capsule, extended release Oral 0.25 mg/1 Injection, solution Tablet Oral 150 mcg Tablet Oral 15000000 mcg Patch Transdermal 0.1 mg/1d Patch Transdermal 0.2 mg/1d Patch Transdermal 0.3 mg/1d Tablet Oral .2 mg Tablet Oral Injection, solution Epidural 0.5 mg/1mL Injection, solution Epidural 100 ug/1mL Injection, solution Epidural 500 ug/1mL Injection, solution Intravenous 100 ug/1mL Injection, solution Intravenous 500 ug/1mL Tablet Oral .1 mg/1 Tablet Oral .2 mg/1 Tablet Oral .3 mg/1 Tablet Oral 0.1 mg/1 Tablet Oral 0.100 mg/1 Tablet Oral 0.2 mg/1 Tablet Oral 0.200 mg/1 Tablet Oral 0.3 mg/1 Tablet Oral 0.300 mg/1 Tablet, extended release Oral 25 mg/1 Capsule, extended release Oral 0.25 MG Tablet Oral 0.3 MG Tablet Oral Injection, solution Epidural 0.1 mg/1mL Injection, solution Intravenous 0.1 mg/1mL Injection, solution Intravenous 0.5 mg/1mL Solution Parenteral 150.00 mcg Solution / drops Ophthalmic Kit Oral Tablet, extended release Oral 0.1 mg/1 Tablet, extended release Oral 0.2 mg/1 For suspension, extended release Oral 0.09 mg/1mL Suspension, extended release Oral 0.09 mg/1mL Tablet, extended release Oral 0.17 mg/1 Tablet, extended release Oral 0.26 mg/1 Tablet Oral .1 mg Tablet Oral 0.025 mg Tablet Oral 0.1 mg Tablet Oral 0.2 mg Tablet Oral 0.15 mg - Prices
Unit description Cost Unit Catapres-TTS-3 4 0.3 mg/24hr Patches Box 328.42USD box CloNIDine HCl 4 0.3 mg/24hr Patches Box 279.9USD box Catapres-TTS-2 4 0.2 mg/24hr Patches Box 236.75USD box CloNIDine HCl 4 0.2 mg/24hr Patches Box 201.75USD box Catapres-TTS-1 4 0.1 mg/24hr Patches Box 141.08USD box CloNIDine HCl 4 0.1 mg/24hr Patches Box 119.84USD box Catapres-tts 3 patch 78.95USD patch Clonidine 0.3 mg/day patch 67.28USD patch Clonidine hcl powder 53.09USD g Clonidine 0.2 mg/day patch 48.5USD patch Duraclon 500 mcg/ml vial 47.4USD ml Catapres-tts 2 patch 39.23USD patch Clonidine 0.1 mg/day patch 28.81USD patch Catapres-tts 1 patch 21.18USD patch Clonidine 5000 mcg/10 ml vial 21.0USD ml Duraclon 0.1 mg/ml vial 14.4USD ml Clonidine 1000 mcg/10 ml vial 5.04USD ml Catapres 0.3 mg tablet 2.98USD tablet Catapres 0.2 mg tablet 2.35USD tablet Catapres 0.1 mg tablet 1.57USD tablet Clonidine hcl 0.3 mg tablet 0.5USD tablet Clonidine hcl 0.2 mg tablet 0.35USD tablet Catapres 0.2 mg Tablet 0.35USD tablet Apo-Clonidine 0.2 mg Tablet 0.33USD tablet Novo-Clonidine 0.2 mg Tablet 0.33USD tablet Nu-Clonidine 0.2 mg Tablet 0.33USD tablet Dixarit 0.025 mg Tablet 0.28USD tablet Clonidine hcl 0.1 mg tablet 0.24USD tablet Catapres 0.1 mg Tablet 0.19USD tablet Apo-Clonidine 0.1 mg Tablet 0.18USD tablet Novo-Clonidine 0.1 mg Tablet 0.18USD tablet Nu-Clonidine 0.1 mg Tablet 0.18USD tablet Apo-Clonidine 0.025 mg Tablet 0.16USD tablet Novo-Clonidine 0.025 mg Tablet 0.16USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5869100 No 1999-02-09 2013-10-13 US US8623409 No 2014-01-07 2031-09-08 US US8337890 No 2012-12-25 2027-04-17 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 130 http://www.chemspider.com/Chemical-Structure.2701.html?rid=816613e6-a54a-46f0-8152-4a93e09e4170 logP 1.59 HANSCH,C & LEO,AJ (1985) Caco2 permeability -4.59 ADME Research, USCD pKa 8.05 (at 25 °C) KONTTURI,K & MURTOMAKI,L (1992) - Predicted Properties
Property Value Source Water Solubility 0.48 mg/mL ALOGPS logP 2.55 ALOGPS logP 2.49 Chemaxon logS -2.7 ALOGPS pKa (Strongest Basic) 8.16 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 36.42 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 59.09 m3·mol-1 Chemaxon Polarizability 21.7 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9632 Blood Brain Barrier + 0.9402 Caco-2 permeable + 0.8866 P-glycoprotein substrate Substrate 0.6305 P-glycoprotein inhibitor I Non-inhibitor 0.9061 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Inhibitor 0.745 CYP450 2C9 substrate Non-substrate 0.8219 CYP450 2D6 substrate Non-substrate 0.6984 CYP450 3A4 substrate Non-substrate 0.6353 CYP450 1A2 substrate Non-inhibitor 0.8998 CYP450 2C9 inhibitor Non-inhibitor 0.7681 CYP450 2D6 inhibitor Inhibitor 0.8931 CYP450 2C19 inhibitor Non-inhibitor 0.8732 CYP450 3A4 inhibitor Non-inhibitor 0.8332 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.803 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.9303 Biodegradation Not ready biodegradable 0.9949 Rat acute toxicity 3.5030 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7232 hERG inhibition (predictor II) Non-inhibitor 0.8905
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 141.5208735 predictedDarkChem Lite v0.1.0 [M-H]- 138.30542 predictedDeepCCS 1.0 (2019) [M+H]+ 142.1236735 predictedDarkChem Lite v0.1.0 [M+H]+ 141.04381 predictedDeepCCS 1.0 (2019) [M+Na]+ 141.6042735 predictedDarkChem Lite v0.1.0 [M+Na]+ 149.7396 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Epinephrine binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
- Gene Name
- ADRA2B
- Uniprot ID
- P18089
- Uniprot Name
- Alpha-2B adrenergic receptor
- Molecular Weight
- 49565.8 Da
References
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [Article]
- Lavand'homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002 Oct;97(4):972-80. [Article]
- Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [Article]
- Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [Article]
- Wang XM, Zhang ZJ, Bains R, Mokha SS: Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002 Jul;98(1-2):27-35. [Article]
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1A
- Uniprot ID
- P35348
- Uniprot Name
- Alpha-1A adrenergic receptor
- Molecular Weight
- 51486.005 Da
References
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- PDSP Ki Database [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- PDSP Ki Database [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Alpha1-adrenergic receptor activity
- Specific Function
- This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
- Gene Name
- ADRA1D
- Uniprot ID
- P25100
- Uniprot Name
- Alpha-1D adrenergic receptor
- Molecular Weight
- 60462.205 Da
References
- Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A: S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205. [Article]
- PDSP Ki Database [Link]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- Curator comments
- Data is limited to an in vitro study.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d 24-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A1
- Uniprot ID
- P04798
- Uniprot Name
- Cytochrome P450 1A1
- Molecular Weight
- 58164.815 Da
References
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Toxin transporter activity
- Specific Function
- Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
- Gene Name
- SLC22A3
- Uniprot ID
- O75751
- Uniprot Name
- Solute carrier family 22 member 3
- Molecular Weight
- 61279.485 Da
References
- Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [Article]
- Martel F, Grundemann D, Calhau C, Schomig E: Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):40-9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [Article]
- Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
- Gene Name
- SLC22A4
- Uniprot ID
- Q9H015
- Uniprot Name
- Solute carrier family 22 member 4
- Molecular Weight
- 62154.48 Da
References
- Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [Article]
Drug created at June 13, 2005 13:24 / Updated at May 21, 2024 16:36